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Erja Kerkelä 
The Expression and Regulation of Matrix Metalloproteinases-12, -10 and -7 in Epithelial Cells 
and Squamous Cell Cancer 
 
Department of Dermatology and Venereology 
Helsinki University Central Hospital and University of Helsinki 
 
ABSTRACT 
 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent enzymes which take part in the 
sophisticated coordination of extracellular matrix (ECM) synthesis and breakdown. Together they 
can cleave essentially all matrix proteins. Degradation of connective tissue is required both in 
normal physiologic processes and in pathologic tissue remodeling such as cancer. The aim of this 
study was to investigate the expression and regulation of metalloelastase (MMP-12), stromelysin-2 
(MMP-10) and matrilysin (MMP-7) in epithelial cancers and to evaluate their role in the clinical 
behavior of tumors. Furthermore, we studied the role of MMP-12 during human development. Our 
results revealed a restricted expression of MMP-12 in hypertrophic chondrocytes in developing 
bone, beginning from the gestational age of 8 weeks, but not in other fetal tissues. Expression of 
MMP-12 mRNA could not be detected in normal adult cartilage or osteosarcomas but in 
chondrosarcomas in both macrophages and cancer cells. TNF-α induced MMP-12 transcription in 
chondrosarcoma-derived cells. 
MMP-12 was detected in basal cell carcinomas (BCCs) and squamous cell carcinomas 
(SCCs) of the skin and vulva both in epithelial cancer cells and macrophages in vivo, as well as in 
various cultured SCC cell lines and transformed HaCaT cells, whereas pre-malignant tumors and 
primary skin keratinocytes were negative. MMP-7 and -12 proteins were also upregulated in areas of 
elastotic material in solar damage, including actinic keratosis, a condition that can develop into SCC. 
In vulvar SCCs, MMP-12 mRNA was expressed in cancer cells only in the histologically more 
aggressive grade II/III samples, thereby correlating with the dedifferentiation of the tumors. In 
contrast, macrophage-derived MMP-12 mRNA was most abundant in well-differentiated grade I 
tumors. The amount of signal for MMP-12, regardless of its origin, did not significantly correlate 
with metastases, the amount of blood vessels or patient survival. MMP-12 production was induced 
by transforming growth factor-β1 (TGF-β1) and tumor necrosis factor-α (TNF-α) in cells derived 
from cutaneous SCC and epithelial MCF-10f cells, while only by TGF-β1 in HaCaTs. In SCCs of 
the vulva, MMP-7 mRNA was detected in 50 % of tumors mainly in epithelial tumor cells, the 
expression generally concentrating in more aggressive tumors. In HaCaTs it was upregulated by 
TNF-α. MMP-10 mRNA was expressed in SCCs and BCCs only in epithelial laminin-5 positive 
cancer cells with a pattern totally different from its close homologue stromelysin-1 (MMP-3). The 
production of MMP-10 was upregulated in cutaneous SCC cells by TGF-α and KGF, and by IFN-γ 
in combination with TGF-β1 and TNF-α, both in SCC and HaCaT cells. 
In conclusion, this study shows that MMP-12 can be expressed in vivo and in vitro by 
transformed epithelial cells. The level of cancer cell derived MMP-12 correlates with histological 
aggressiveness, while that of macrophages predicts less aggressive behavior of the tumors, 
suggesting a dual role for MMP-12 in cancer progression. According to the present results, there is a 
possibility that MMP-12 mRNA expression in m acrophages might serve as a new prognostic marker 
in patients with SCC. Furthermore, MMP-12 plays an important role in ECM remodeling during 
fetal bone development and is induced when chondrocytes undergo malignant transformation. In 
contrast, MMP-10 expression does not correlate with the invasive behavior of SCCs but may be 
induced by the wound healing and inflammatory matrix remodeling events associated with skin 
tumors. 
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1. INTRODUCTION 
 
Controlled degradation of ECM macromolecules is critical for many normal biological processes, 
such as reproduction, wound healing and fetal development. On the other hand, excessive 
degradation of matrix components can lead to pathologic tissue destruction occurring, for example, 
in inflammatory and cardiovascular diseases, and in cancer. Matrix metalloproteinases (MMPs) are 
degradative enzymes that seem to play an important role in all aspects of tumor progression by 
enhancing tumor-induced angiogenesis and destroying local tissue architecture and basement 
membranes to allow tumor invasion and metastasis. Efficient breakdown of the ECM surrounding 
invasive cancer islands involves interplay between tumor cells, stromal cells, and inflammatory 
cells, all of which express a distinct set of MMPs. Besides the classical role of MMPs in 
degradation of ECM in tumorigenesis, MMPs may also indirectly influence the tumor 
microenvironment through the release of growth factors, cryptic sites or angiogenic factors, or 
through the generation of matrix fragments that inhibit tumor cell proliferation, migration and 
angiogenesis. This makes the contribution of MMPs to tumorigenesis much more complex than 
initially thought. 
 
To date, over 20 MMPs have been characterized. They share several structural and functional 
characteristics and together they are able to degrade practically all proteins of the ECM. According 
to their structural features and substrate specificity, they are divided into the subgroups of 
collagenases, gelatinases, stromelysins and stromelysin-like MMPs, matrilysins, membrane-type 
MMPs and other MMPs. 
 
The aim of this study was to investigate the role and expression of metalloelastase (MMP-12), 
stromelysin-2 (MMP-10) and matrilysin (MMP-7) in premalignant lesions of the skin as well as in 
epithelial cancers both in vivo and in vitro, and to evaluate the role of MMP-12 in the clinical 
behavior of squamous cell carcinomas (SCC), in particular. Regulation of these MMPs was studied 
in various cultured epithelial cell lines, including different SCC cells and transformed HaCaT 
keratinocytes. Furthermore, we studied the role of MMP-12 during human development and in bone 
lesions. The principal methods used include in situ hybridization, immunohistochemistry, cell 
culture, Northern analysis, Western blot, and quantitative RT-PCR. 
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2. REVIEW OF THE LITERATURE 
 
2.1. STRUCTURE OF THE SKIN 
 
Human skin is the largest multifunctional organ of the body (Figure 1). It has multiple specified 
tasks, such as supporting the body with connective tissue, and protection from external injuries, 
micro-organisms and radiation. It also provides sensation, thermoregulation, and 
biochemical/metabolic and immune functions. The skin can be divided into an upper epithelial layer, 
epidermis, and an underlying connective tissue, dermis. These are separated by the basement 
membrane zone. Epithelium is not only found in skin, since epithelial cells also cover internal body 
cavities and tubes. In addition, they cover or line all the body organs, including organs of the 
digestive system. Epithelium also forms the secretory portion of the glands and their ducts. Different 
kinds of epithelia can be roughly divided into simple and stratified epithelium (Chan 1997; Archer 
1998). 
 
2.1.1. Epithelium 
 
The stratified squamous epithelium of the skin consists mainly of keratinocyte layers (Figure 1). It 
contains also melanocytes, which produce pigment, Langerhans cells, which can process and 
introduce antigens, and Merkel cells. The epidermis has four layers: the basal, squamous and 
granular cell layer, and the stratum corneum. Basal cells form a single cell layer on an intact 
basement membrane. The epidermis regenerates constantly as basal cells divide and migrate towards 
the surface. Basal cells are rounded and flatten out as they differentiate. At the same time, nuclei 
disappear and cells get filled with keratin filaments and keratohyalin. Flattened cells provide a tight 
layer to protect the skin from external irritants. Finally, superficial flattened cells mainly contain 
keratinfilaments and are sloughed from the stratum corneum. (see Eckert 1989; Lever and 
Schaumburg-Lever, 1990a) 
 
 
   Figure 1. Structure of the skin (modified from Alberts et al, 1994b). 
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2.1.2. Extracellular matrix 
 
The extracellular matrix (ECM) of interstitial connective tissue is formed by complex and intricate 
networks in which protein molecules are precisely organized. These networks determine the specific 
architecture of the tissues and provide cells with biological information and substratum for adhesion 
and migration. The variation in the relative amounts of macromolecular components and their 
organization in different tissues, together with the different cells present, create the diversity of the 
form of connective tissue ranging from bone to transparent matrix of the cornea. In interstitial 
connective tissue, the ECM is secreted by fibroblasts, and by some specialized cells such as 
chondrocytes in cartilage and osteoblasts in bone. The two main classes of macromolecules that 
making up the matrix are 1) fibrous proteins of two functional types: mainly structural (collagen and 
elastin) and mainly adhesive (fibronectin and laminin), and 2) proteoglycans, proteins with 
covalently linked polysaccharide chains called glycosaminoglycans (GAGs). Most of the structural 
ECM molecules, including collagens, noncollagenous glycoproteins and proteoglycans, are chimeric 
and share common domains. Besides fibroblasts, there are other cells present; mast cells are 
particularly abundant in skin, nasal mucosa and gut, but can be found in other tissues as well. 
Macrophages have many functions, e.g., phagocytosis, antigen presentation and secretion of growth 
factors. Plasma cells are B lymphocytes which produce antibodies. Furthermore, there are many 
blood-derived cells in the ECM, including neutrophils, eosinophils, monocytes and lymphocytes 
(Figure 1) (see Alberts et al, 1994a; Aumailley and Gayraud, 1998). 
 
2.1.2.1. Connective tissue components 
 
Collagen is the most abundant structural component of the ECM and also the most abundant protein 
in the human body. The collagen gene family has now over 30 members, which code 19 different 
proteins (Trojanowska et al, 1998). They are secreted by a variety of cells including the cells of the 
interstitial connective tissue. The distribution and amount of each type varies greatly in different 
tissues. A characteristic property of collagens is to form highly organized, stiff, triple-stranded 
polymers in which three polypeptides, α-chains, are wound around one another in a ropelike 
superhelix. They are rich in proline, hydroxyproline and glycine and have classical Gly-X-Y triplets 
in their triplehelical domains of the polypeptides. Most of the collagens are synthesised as 
procollagens and processed in the extracellular space (Prockop and Kivirikko, 1995). Collagens can 
be divided into subgroups according to their structure and distribution. The main collagen types 
found in connective tissue are fibrillar collagens, i.e. type I, II, III, V and XI collagens. Type I and 
III are the major collagens in skin, and type I and II in the bone and cartilage. The type I collagen 
fibers provide mechanical strength while type III collagen gives flexibility to the tissues (Mauch and 
Krieg, 1993). Nonfibrillar collagens form sheet-like structures or connect ECM components to 
collagen fibrils (Prockop and Kivirikko, 1995; Aumailley and Gayraud, 1998). They include 
network-forming collagens (IV, VIII, X), fibril-associated collagens with interrupted triple helices 
(FACIT) (IX, XII, XIV, XVI, XIX), membrane-associated collagens with interrupted triple helices 
(MACIT) (XIII, XVII), proteins with multiple triple-helical domains and interruptions 
(MULTIPLEXINs) (XV, XVIII) and orphans (VI, VII) (Pihlajaniemi and Rehn, 1995). 
 
Elastin and elastic fibers: The elastic properties of many tissues such as the lung, dermis and the 
large blood vessels are due to the presence of elastic fibers in the extracellular space. The elastic 
fiber is a complex structure containing elastin, microfibrillar proteins, lysyl oxidase, and probably, 
proteoglycans. Elastin is the predominant protein of mature elastic fibers and endows the fiber with 
the characteristic property of elastic recoil. Elastin is widely distributed in vertebrate tissues and 
possesses an unusual chemical composition rich in glycine, proline, hydrophobic amino acids 
(elastic repeats), as well as alanine-rich, lysine-containing domains that form crosslinks, all 
consistent with its characteristic physical properties. It performs various functions, acting statically 
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in dermis to endure long-term forces and dynamically in arteries to store and release energy rapidly. 
It is secreted as a soluble precursor, tropoelastin, before forming the amorphous component of 
elastic fibres. Tropoelastin is secreted into the extracellular space where it becomes highly cross-
linked into a rubber-like network through the activity of lysyl oxidase. In elastin gene, hydrophobic 
and cross-linking domains are encoded in separate exons and there is significant alternative splicing, 
resulting in multiple isoforms. The elastin gene promoter contains many potential binding sites for 
various modulating factors, suggesting a complex pattern of transcriptional regulation. The 
microfibrils contain several proteins, including fibrillin (Sakai et al, 1986), and probably act as an 
organizing scaffold in the formation of the elastin network. Elastin is produced e.g. in endothelial 
cells and skin fibroblasts. Of the proteolytic enzymes, only elastases can properly degrade elastin 
(Mechan et al, 1991; Rosenbloom et al, 1993; Debelle and Tamburro, 1999). 
 
Proteoglycans (PGs) are found primarily in the ECM or associated with the cell surface, where they 
bind to other matrix- and cell-associated components. They include a group of complex 
macromolecules in which one or more polysaccharide chains are linked to a central protein core. 
The predominant polysaccharides are known as glycosaminoglycans and consist of repeated 
disaccharides. PG structures are diverse in type, size and composition of polysaccharide attached, as 
well as in primary sequence, domain arrangement, degree of substitution and distribution of the 
polysaccharide chains along the protein core. Although there are common features among the 
glycosaminoglycans, six distinct classes are recognized according to fine structural differences: e.g., 
chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, as well as keratan sulfate and 
hyaluronate. There are more than 40 different full-length core proteins, e.g., the aggrecan gene 
family which consists of four distinct proteins: aggrecan, versican, neurocan and brevican. Several 
other families of PGs are known, e.g., the cell-associated proteoglycans comprising the integral 
membrane syndecan family and the BM proteoglycan, perlecan, as well as small interstitial PGs 
decorin and biglycan. PGs carry out a variety of biological functions, including growth modulation, 
ionic filtration, matrix organization, cell-adhesion and structural scaffolds. Spatial immobilization of 
growth factors and cytokines may be one of the most important functions of proteoglycans (Wight et 
al, 1991; Schwartz 2000). 
 
Fibronectin, a high molecular weight glycoprotein synthesized by many types of cells, is involved in 
the attachment of cells to the surrounding ECM. Fibronectin has affinity to the other main 
components of ECM, e.g., collagen and glycosaminoglycans. It also interacts with cell surface 
integrins. The attachment of cells to fibronectin (or the lack of it) plays a significant role in 
morphogenetic events, since during development, embryonic cells migrate on or through fibronectin-
rich matrices and get cues that direct the cells along their migratory pathways. Malignantly 
transformed cells tend to lack cell-associated fibronectin. If fibronectin is indeed the main 
mechanism that anchors cells to the ECM, disturbances of this mechanism could play an important 
role in malignancy and many other diseases (see Yamada 1991; Ruoslahti 1999; Armstrong et al, 
2000). 
 
Integrins comprise a large family of transmembrane glycoprotein receptors that mediate cell-matrix 
or cell-cell adhesion and can transduce signals that regulate gene expression and cell functions. 
These signals regulate the activities of cytoplasmic kinases, growth factor receptors, and ion 
channels and control the organization of the intracellular actin cytoskeleton. Many integrin signals 
concentrate on cell cycle regulation, directing cells to live or die, to proliferate, or to exit the cell 
cycle and differentiate (Giancotti and Ruoslahti, 1999). Integrins are composed of two subunits, α 
and β, and each αβ combination (currently more than 20) has its own binding specificity and 
signaling properties. Most integrins recognize several ECM proteins. Conversely, individual matrix 
proteins, such as fibronectin, laminins, collagens and vitronectin, bind to several integrins 
(Petruzzelli et al, 1999). Integrins can signal through the cell membrane in either direction: the 
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extracellular binding activity of integrins is regulated from the inside of the cell (inside-out 
signaling), while the binding of the ECM elicits signals that are transmitted into the cell (outside-in 
signaling) (see Giancotti and Ruoslahti 1999). 
 
Tenascins comprise a family of strikingly large ECM glycoproteins, presently including tenascins -
C, -R, -W, -X, and -Y. Tenascin is a special cell interaction protein capable of mediating both 
adhesive and repulsive interactions as well as binding to certain proteoglycans and fibronectin. It has 
a characteristic hexameric quaternary structure with six arms linked to a central globular domain. 
Tenascins are tightly regulated and display highly restricted and dynamic patterns of expression. 
Their expression is closely associated with morphogenetic events, including embryonic migration 
and induction particularly during neural development, skeletogenesis, and vasculogenesis. These 
molecules are reexpressed in the adult during normal processes, such as wound repair, nerve 
regeneration, and tissue involution, as well as in pathological conditions like vascular disease and 
tumorigenesis (Yamada et al, 1996; Jones et al, 2000). 
 
2.1.2.2. Dermis 
 
The connective tissue of the skin, the dermis, is derived from the mesoderm. It consists of 
collagenous and elastic fibers embedded into ground substrate. All three components are formed by 
fibroblasts. The dermis is divided into subepithelial papillary dermis of the loose connective tissue 
and reticular layer, which lie on adipose tissue (Figure 1). The papillary dermis has numerous blood 
vessels that penetrate from the deeper layers. Collagen fibers form a finely woven meshwork. The 
reticular layer has thick collagen bundles and it comprises the largest portion of the dermis. A small 
number of fibroblasts are interspersed between the collagen bundles. Dermis consists mainly of 
fibrillar collagens type I and type III (75 % of dry weight). Thin elastic fibers (1 %) are found 
throughout the dermis between the collagen bundles. The amorphous ground substrate consists 
mainly of proteoglycans, including dermatan sulfates, hyaluronic acid, chondroitin and heparan 
sulfates (see Lever and Schaumburg-Lever, 1990a; Archer et al, 1998). 
 
2.1.3. Basement membrane 
 
Basement membranes (BM) are highly specialized structures that separate basal cells from 
underlying connective tissue. Their structure is relatively similar in different organs. The cutaneous 
BM zone is located between the epidermis and the dermis and is called the dermal-epidermal 
junction (DEJ) (Figure 2). Besides separating two distinct compartments, DEJ provides adhesion 
and dynamic interface between them, thus determining the overall structural integrity of the skin. 
The DEJ restricts the movement of molecules between two compartments on the basis of size and 
charge, but it allows the passage of migrating and invading cells under normal (i.e. melanocytes and 
Langerhans cells) or pathological (i.e. lymphocytes and cancer cells) conditions. It also supports the 
epidermis and influences the behavior of keratinocytes by regulating cell polarity, proliferation, 
migration and differentiation. In addition, its role is important during morphogenesis and 
development, wound healing and remodeling of the skin (see Burgeson and Christiano, 1997). 
 
Ultrastructurally, the DEJ is divided into four zones. First, the cell membranes of the basal 
keratinocytes contain multiprotein junctional complexes called hemidesmosomes, into which the 
epithelial cytokeratins insert (Figure 2). Lamina lucida is an electron-lucent region, which anchoring 
filaments pass through. Lamina densa, an electron-dense area, is connected to hemidesmosomes 
with anchoring filaments. Sub-lamina densa contains anchoring fibrils (Chan 1997). Each of these 
zones also contains ubiquitous BM components, e.g. laminin and nidogen in upper regions, network-
forming type IV collagen and heparan sulphate proteoglycan (perlecan) mainly in lamina densa, and 
type VII collagen, the major component of the anchoring fibrils in the sub-lamina densa. Epithelial 
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cells generally attach to the BM via actin, α3β1 integrin and laminins (laminins 10/11, 5 and 6/7), 
which, in turn, connect to type IV collagen via nidogen (Burgeson and Christiano, 1997). 
 
 
      Figure 2. Proposed structure of the BM and hemidesmosome (modified from Burgeson and  
      Christiano, 1997). This model depicts the relative locations of the molecules situated within 
      the DEJ and interactions assumed to occur between them. 
 
 
In stratified epithelia, such as in skin, and other complex epithelia (e.g., cornea, parts of the 
gastrointestinal tract), hemidesmosomes (HD) promote the adhesion of epithelial cells to the 
underlying BM. They consist of three classes of proteins: the cytoplasmic plaque proteins, plectin 
(McLean et al, 1996), bullous pemphigoid antigen (BPAG) 1 (Stanley et al, 1988) together with 
intermediate filament associated protein and HD 1, act as linkers of the cytoskeleton; the 
transmembrane proteins, α6β4 integrin (Stepp et al, 1990; Sonnenberg et al, 1991) and BPAG 2 
(also known as collagen XVII) (Giudice et al, 1992), connect the cell interior to the ECM; finally, 
the BM associated proteins of the ECM, such as laminin-5 (kalinin) (Rousselle et al, 1991), which is 
linked to type VII collagen (Rousselle et al, 1997). Laminin-5 is a cruciform-shaped molecule 
consisting of three nonidentical chains within a supramolecular network. Laminin-5 supports cell 
binding and spreading and is a major ligand for the α6β4 integrin. Interaction between these two 
molecules seems to be crucial for the formation of HD and the maintenance of stable adhesion 
(Borradori and Sonnenberg, 1999). α6β4 integrin is able to transduce signals from the ECM to the 
interior of the cell, which critically modulate the organization of the cytoskeleton, proliferation, 
apoptosis, and differentiation, all processes of crucial importance in development, wound healing 
and tumor invasion. It has been suggested that cancer cells use the interaction between α6β4 
integrin and laminin-1 and -5 as their mechanism of adhesion during the invasion through 
surrounding tissues (Tani et al, 1996). Besides interaction with α6β4, laminin-5 can also bind to the 
α6β1 and α3β1 integrins. In quiescent tissues, it may predominantly be a static adhesive substrate, 
while during regenerative or wound healing responses it may have a major role in epithelial cell 
motility through action involving matrix metalloproteinase cleavage (Giannelli et al, 1997; 
Koshikawa et al, 2000). Laminin-5 is actually the first ECM component to be expressed and 
deposited by migrating keratinocytes during wound healing in vivo (Zhang and Kramer, 1996). 
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2.2. PROTEOLYTIC REMODELING OF THE ECM 
 
The coordinated degradation of the ECM macromolecules is critical for many biological processes. 
Proteolytic activity is required in normal physiologic processes, such as reproduction (ovulation, 
menstruation and mammary gland involution), wound healing, angiogenesis and fetal development. 
However, excessive degradation of matrix components occurs in pathologic tissue destruction, e.g., 
in chronic wounds, dermal photoageing, bullous skin diseases, atherosclerosis, rheumatoid arthritis, 
as well as tumor cell invasion and metastasis (see Birkedal-Hansen et al, 1993; Kähäri and 
Saarialho-Kere, 1997; Nagase and Woessner, 1999; Curran and Murray, 2000; Ravanti and Kähäri, 
2000). Remodeling of the ECM requires cooperation of many different protease systems. ECM 
degrading proteolytic enzymes can be divided into four subgroups according to their amino acid 
residue or cofactor required for catalytic activity. 1) Cysteine proteases include two superfamilies, 
and for example most cathepsins belong to this group (Chapman et al, 1997). 2) Aspartic proteases 
include, e.g., cathepsins D and E, renin and pepsin (Hoegl et al, 1999). 3) Serine proteases include 
for instance, tissue-type and urokinase-type plasminogen activators (tPa, uPa), thrombin, furin and 
plasmin (Plow et al, 1995). 4) Metalloproteinases contain a metal ion in the catalytic site. They can 
be further divided into several superfamilies. The members of one superfamily, the metzincins, bind 
zinc at the catalytic site and they have conserved “Met-turn” motif, as well as conserved structural 
topology. Metzincins consist of four groups; serralysins, matrixins (matrix metalloproteinases), 
astacins and adamalysins (see Stöcker et al, 1995; Bergers and Coussens, 2000a). 
 
2.2.1. Matrix Metalloproteinases (MMPs) 
 
Matrix metalloproteinases are a group of enzymes which together can degrade all the known protein 
components of the ECM. The first MMP member, collagenase, was found in the tadpole tail (Gross 
and Lapière, 1962). Presently, the MMP gene family consists of 21 members and the family is still 
growing. MMPs are products of different genes dispersed to the genome, although there is an MMP 
gene cluster in choromosome 11 (Massova et al, 1998). MMPs differ structurally and by the fact that 
each MMP has the ability to degrade a particular subset of matrix proteins. The protein products are, 
however, classified by shared functional and structural characteristics (Figure 3). MMPs can be 
divided into the following subgroups: 1) collagenases, 2) gelatinases, 3) stromelysins and 4) 
stromelysin-like MMPs, 5) membrane type (MT) MMPs, and 6) other MMPs according to their 
structure and substrate specificity (Table I) (see Birkedal-Hansen et al, 1993; Nagase and Woessner, 
1999). It is important to remember that most of the MMP substrates defined to date have been 
demonstrated in vitro and their importance in biological context is not known. 
 
The N-terminal signal peptide, rich in hydrophobic amino acids, directs the protein for secretion into 
the endoplasmic reticulum and, eventually, out of the cell. All except MMP-17 (Puente et al, 1996) 
have a signal peptide. MMP-23 has a signal anchor, which binds it to the cell surface (Pei et al, 
2000). All MMPs have a pro-domain acting as an internal inhibitor to keep the enzyme inactive until 
proteinase activity is required. It contains a highly conserved sequence, which has cysteine residue 
binding the catalytic zinc ion and thus keeping the proMMP in latent form. Activation occurs with 
disruption of the Cys-zinc bond and cleavage of the pro-domain leading to a conformational change 
to the catalytically active form (Van Wart and Birkedal-Hansen, 1990). The catalytic core-domain 
contains the active, protein-degrading ability of the proteinase. This domain includes a metal-
binding site for Zn2+, the binding of which is essential for proteolytic activity (and explains the word 
'metallo' in its name). MMPs are classified on the basis of additional protein domains that contribute 
to their individual characteristics (Nagase and Woessner, 1999). A proline-rich hinge region 
connects the catalytic domain to the following hemopexin domain. The active form of matrilysins 
contains only the catalytic domain characteristic of all MMPs. Structurally unique MMP-23 also 
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lacks the hemopexin domain. All other MMPs have an additional C-terminal domain with homology 
to a serum protein called hemopexin. There is a cysteine residue at both ends, which fold the domain 
into a four-bladed propeller structure. The hemopexin domain is suspected to mediate additional 
protein–protein interactions with substrates and with naturally occurring inhibitors TIMPs (Sanchez-
Lopez et al, 1993; Baragi et al, 1994). 
 
In some of the MMP members there are additional functional domains present. Fibronectin type II 
inserts in the catalytic domain of gelatinases modulate protein interactions important in substrate 
(gelatin) recognition (Murphy et al, 1994). The transmembrane domain in the C-terminus localizes 
some cell-surface-bound MMPs to the cell membrane and short sequence between the prodomain 
and the catalytic domain, i.e. furin domain provides an alternative cleavage site for MMP activation 
(Nagase and Woessner, 1999). These different combinations of protein motifs within the MMP 
family, together with individual gene sequences, generate the wide variety of characteristics within 
it. 
 
     Figure 3.  Structure of  matrix metalloproteinases  (modified  from  
     Johansson and Kähäri, 2000). s, signal anchor; C.A., cysteine array 
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Table I. Human Matrix Metalloproteinases 
Enzyme Substrates Activator of Activated by 
Collagenases    
Collagenase-1 (MMP-1) Col I, II, III, VII, VIII, X, aggrecan, MBP, serpins, 
α2M, perlecan, TNF precursor, IGFBP, α1P1 
MMP-2 MMP-3, -10, 
plasmin, kallikrein, 
chymase 
Collagenase-2 (MMP-8) Col I, II, III, aggrecan, serpins, α2M, fibrinogen ND MMP-3, -10, plasmin 
Collagenase-3 (MMP-13) Col I, II, III, IV, IX, X, XIV, aggrecan, fibrillin, 
fibronectin, gelatin, LN-1, large tenascin C, 
osteonectin, serpins, PAI, fibrinogen 
MMP-2, -9 MMP-2, -3, -10, -14, 
-15, plasmin 
Gelatinases    
Gelatinase A (MMP-2) Col, I, IV, V, VII, X, gelatin, fibronectin, tenascin, 
fibrillin, osteonectin, MBP, decorin, α2M, LN-5, 
IGFBP, TNF precursor, TGF-β 
MMP-9, -13 MMP-1, -7, -13, -14, 
-15, -16, -24, -25, 
tryptase, thrombin, 
plasmin 
Gelatinase B (MMP-9) Col IV, V, VII, XI, XIV, XVII, gelatin, elastin, 
fibrillin, osteonectin, fibronectin, MBP, α2M, TNF 
precursor, IGFBP, plasminogen, TGF-β, α1P1 
ND MMP-2, -3, -13, 
plasmin 
Stromelysins and 
stromelysin-like MMPs 
   
Stromelysin-1 (MMP-3) Col IV, V, VII, IX, X, XIV, elastin, fibronectin, 
fibrillin, gelatin, aggrecan, LN-1, nidogen, 
osteonectin, decorin, α1P1, TNF precursor, MBP, 
E-cadherin, β-catenin, IGFBP 
MMP-1, -7, 
-8,-9,-13 
Plasmin, kallikrein, 
chymase, tryptase 
Stromelysin-2 (MMP-10) Col IV, V, IX, X, XIV, elastin, fibronectin, gelatin, 
aggrecan, LN-1, nidogen 
MMP-1, -8, 
-13 
Elastase, cathepsin G, 
plasmin 
Stromelysin-3 (MMP-11) α1P1, IGFBP ND Furin 
Metalloelastase (MMP-12) Elastin, col IV, fibronectin, LN-1, gelatin, 
vitronectin, entactin, proteoglycan, heparan and 
chondroitin sulfates, TNF precursor, plasminogen, 
fibrillin, fibrinogen 
MMP-2, -3 Plasmin 
Matrilysins    
Matrilysin-1 (MMP-7) Col IV, elastin, fibronectin, LN-1, nidogen, 
tenascin, osteonectin, MBP, decorin, versican, 
α1P1, osteopontin, E-cadherin, plasminogen, β4 
integrin, α-prodefensin, Fas ligand 
MMP-2, -9 
 
MMP-3, plasmin 
Matrilysin-2 (MMP-26, 
endometase) 
Col IV, gelatin, fibronectin, fibrin, α1PI, β-casein, 
TACE-substrate 
MMP-9 ND 
Membrane-type MMPs    
MT1-MMP (MMP-14) Col I, II, III, gelatin, fibronectin, LN-1, vitronectin, 
aggrecan, tenascin, nidogen, perlecan, fibrinogen/ 
fibrin, fibrillin, α1PI, α2M, LN-5, CD-44 
MMP-2, -13 Plasmin, furin 
MT2-MMP (MMP-15) Fibronectin, LN-1, aggrecan, tenascin, nidogen, 
perlecan 
MMP-2, -13 ND 
MT3-MMP (MMP-16) Col III, fibronectin, gelatin, laminin, aggrecan, 
casein, vitronectin, α2M, α1PI 
MMP-2 ND 
MT4-MMP (MMP-17) Gelatin, TNF-α precursor, fibrillin, fibronectin ND ND 
MT5-MMP (MMP-24) ND MMP-2 ND 
MT6-MMP (MMP-25) Col IV, gelatin, fibronectin, fibrin MMP-2 ND 
Other MMPs    
MMP-19 Col IV, gelatin, LN-1, nidogen, tenascin, 
fibronectin, aggrecan, COMP 
ND Trypsin 
Enamelysin (MMP-20) Amelogenin, aggrecan, COMP ND ND 
MMP-23 Aggrecan, COMP ND ND 
Epilysin (MMP-28) ND ND ND 
(Modified from Murphy and Knäuper, 1997; Johansson and Kähäri, 2000; McCawley and Matrisian, 2001) Col, 
collagen; COMP, cartilage oligomeric matrix protein; IGFBP, insulin-like growth factor binding protein; LN, laminin; 
MBP, myelin basic protein; PAI, plasminogen activator inhibitor; TACE, TNF-α converting enzyme; α2M, α2-
macroglobulin; α1PI, α1-proteinase inhibitor; ND, not detected 
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2.2.1.1. Collagenases 
 
Collagenases-1, -2 and -3 are the major secreted proteinases capable of initiating degradation of 
native fibrillar collagens (type I, II, III, V and IX) and obviously play a crucial role in degradation of 
collagenous ECM in various situations. The fibrillar collagens are cleaved at a specific site to 
produce ¾ N-terminal and ¼ C-terminal triple helical fragments, which denaturate spontaneously to 
gelatin at 37°C. These fragments can be further degraded by other MMPs, such as gelatinases (see 
Birkedal-Hansen et al, 1993). MMP-1, the first MMP determined by cDNA cloning (Goldberg et al, 
1986), cleaves preferentially type III collagen while MMP-8 cleaves type I and II collagens (Welgus 
et al, 1981; Hasty et al, 1987). MMP-13 cleaves preferentially type II collagen and also gelatin more 
effectively than other collagenases (Knäuper et al, 1996a). In vitro MMP-1 is expressed in various 
normal cells, such as keratinocytes, fibroblasts, endothelial cells, monocytes, macrophages and 
chondrocytes (see Birkedal-Hansen et al, 1993). It can be detected in vivo in many physiological 
situations, including embryonic development and wound healing, but also in chronic cutaneous 
ulcers and many cancers (McGowan et al, 1994; Saarialho-Kere 1998; Stetler-Stevenson et al, 
2001). MMP-8 is synthesized by maturing leukocytes in bone marrow, stored intracellularly in 
granules and released in response to extracellular stimuli (Hasty et al, 1986; Hasty et al, 1990). In 
addition, it has been detected in human articular cartilage chondrocytes, mononuclear fibroblast-like 
cells in the rheumatoid synovial membrane, and more recently, in gingival fibroblasts and bronchial 
epithelial cell (Cole et al, 1996; Hanemaaijer et al, 1997; Abe et al, 2001; Prikk et al, 2001). MMP-
13 was originally cloned from a breast tumor cDNA library (Freije et al, 1994) and has a potent 
degrading activity against an exceptionally wide spectrum of substrates. It is expressed during fetal 
bone development, bone remodeling, and gingival wound repair (Ståhle-Bäckdahl et al, 1997; 
Johansson et al, 1997b; Ravanti et al, 1999), as well as pathological situations, such as chronic 
cutaneous ulcers (Vaalamo et al, 1997), rheumatoid arthritis (Ståhle-Bäckdahl et al, 1997), 
periodontitis (Uitto et al, 1998) and various invasive tumors, e.g. squamous cell carcinomas of 
different organs, chondrosarcomas and melanoma (Johansson et al, 1997c; Uria et al, 1998; Airola 
et al, 1999; Pendas et al, 2000). 
 
2.2.1.2. Gelatinases 
 
Gelatinase A (MMP-2, also known as 72 kDa gelatinase) is expressed in a variety of normal and 
transformed cells, including fibroblasts, keratinocytes, endothelial cells, chondrocytes, and 
osteoblasts. Gelatinase B (MMP-9, 92 kDa gelatinase) is produced by keratinocytes, monocytes, 
macrophages, PMN (polymorphonuclear) leukocytes and a large variety of malignant cells. 
Gelatinases are able to degrade type IV, V, VII, X, XI, and XIV collagens, gelatin, elastin, 
proteoglycan and fibronectin among others (Birkedal-Hansen et al, 1993). They have three tandem 
fibronectin type repeats in the catalytic domain, which are important for elastolytic activity (Shipley 
et al, 1996a). MMP-9 also has a unique proline-rich domain with unknown function homologous to 
the α2-chain of type V collagen between catalytic and hemopexin-like domains (Wilhelm et al, 
1989). Gelatinases are believed to have a particularly important role in cancers due to their capacity 
to cleave BM components (Birkedal-Hansen 1995). MMP-2 is regulated differently from other 
MMPs and it is believed to have a unique role in cell-matrix interactions, including cancer invasion 
(Yu et al, 1996). Furthermore, MMP-2 knock-out mice exhibit reduced angiogenesis, impared tumor 
growth and decreased metastasis (Itoh et al, 1998). In MMP-9-deficient mice, hypertrophic 
chondrocytes develop normally, but apoptosis, vascularization, and ossification are delayed, 
resulting in progressive lengthening of the growth plate (Vu et al, 1998). These mice are also 
resistant to blister formation in an experimental bullous pemphigoid model (Liu et al, 1998). 
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2.2.1.3. Stromelysins and stromelysin-like MMPs 
 
Stromelysins-1 and -2 (MMPs-3 and -10) are highly homologous in primary structure and substrate 
specificity. They have been shown to degrade in vitro, e.g., collagen III and IV, gelatin, casein, 
aggrecan, elastin, and proteoglycan core proteins (Murphy et al, 1991b; Chandler et al, 1997) and 
MMP-3 also osteopontin and serine proteinase inhibitors α1-proteinase inhibitor and α1-antitrypsin 
(Winyard et al, 1991; Zhang et al, 1994; Agnihotri et al, 2001). It is expressed by a variety of cells, 
e.g., keratinocytes, fibroblasts and chondrocytes. MMP-3 is expressed by stromal cells during 
normal mammary development and is strongly upregulated during post-lactational mammary 
involution (Witty et al, 1995; Lund et al, 1996). It alters the cellular microenvironment and can act 
as a natural tumor promoter and influence mammary tumor initiation (Sternlicht et al, 1999). 
 
MMP-10 was initially identified in an adenocarcinoma cDNA library (Muller et al, 1988), and since 
then its expression has been associated with cancer invasion, mostly in tumours of epithelial origin 
(Muller et al, 1991; Polette et al, 1991). It was later isolated also from a rheumatoid synovial cell 
cDNA library and shown to be differentially expressed from MMP-3 in human foreskin and 
rheumatoid synovial fibroblasts (Sirum et al, 1989). By Northern analysis, MMP-10 has been 
detected in tumor cells at least in SCCs of the head and neck and lung (Muller et al, 1991), and also 
in hepatocellular carcinoma using immunoblotting (Lichtinghagen et al, 1995). Furthermore, MMP-
10 has an important role in cutaneous and intestinal wound healing. It is expressed at the wound 
edge by migrating basal keratinocytes during both human and murine wound repair (Saarialho-Kere 
et al, 1994; Madlener et al, 1996) and by migrating enterocytes in inflammatory bowel disease 
(Vaalamo et al, 1998). MMP-10 expression is important for the normal repair process and is 
upregulated by cytokines rather than cell-matrix interactions (Rechardt et al, 2000). Furthermore, 
MMP-3 and -10 are differentially expressed in human bone (Bord et al, 1998) and they play a 
critical role in the activation of procollagenases-1 (MMP-1), -2 (MMP-8) and -3 (MMP-13) 
(Nicholson et al, 1989; Knäuper et al, 1996b; Nagase 1998). 
 
Stromelysin-3 (MMP-11) has been cloned from invasive breast cancer tissue (Basset et al, 1990). It 
is expressed in mesenchymal cells located close to epithelial cells during physiological and 
pathological tissue remodeling processes. It has a furin cleavage site in its prodomain and thus is 
processed intracellularly before being released as a mature enzyme (Pei and Weiss, 1995). It is 
expressed in most invasive human carcinomas, and high MMP-11 levels are associated with a poor 
clinical outcome e.g. in breast cancer, suggesting a role during malignant processes (Rouyer et al, 
1994). Mice lacking MMP-11 show reduced tumorigenesis in response to chemical mutagenesis 
(Masson et al, 1998). It does not seem to cleave matrix components but may increase tumorigenesis 
by decreasing cancer cell death (Boulay et al, 2001). 
 
Human macrophage metalloelastase (HME, MMP-12) is often considered a member of the 
stromelysin subgroup. It was initially found in alveolar macrophages of cigarette smokers (Shapiro 
et al, 1993). Metalloelastase is the most effective MMP against elastin but has a broad selection of 
substrates including type IV collagen, fibronectin, laminin, gelatin, vitronectin, entactin, 
proteoglycan, heparan and chondroitin sulfates, α1-antitrypsin, myelin basic protein, and fibrinogen 
(Chandler et al, 1996; Gronski et al, 1997; Hiller et al, 2000). The expression of MMP-12 in vivo 
has been demonstrated mainly in macrophages, for example, in intestinal ulcerations (Vaalamo et al, 
1998) and cutaneous diseases associated with granulomas or macrophage migration (Vaalamo et al, 
1999). Furthermore, it degrades elastic fibers in atherosclerosis (Halpert et al, 1996), and aneurysms 
(Curci et al, 1999). MMP-12 deficient mice have impaired macrophage-mediated proteolysis and 
tissue invasion (Shipley et al, 1996b) and do not develop emphysema like wild-type mice 
(Hautamäki et al, 1997). Interestingly, granulocyte-macrophage colony-stimulating factor (GM-
CSF) stimulates tumor-infiltrating macrophages to produce metalloelastase, which cleaves 
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plasminogen into angiostatin (Dong et al, 1997; Cornelius et al, 1998). Thus, MMP-12 may prevent 
tumor growth by inhibiting angiogenesis. MMP-12 is also able to reduce the number of functional 
urokinase-type plasminogen activator reseptors (uPAR) on endothelial and tumor cells. This leads to 
decrease in uPA binding, and since uPA is needed in the invasion and formation of new capillary 
structures, it inhibits angiogenesis and ultimately also tumor invasion and metastasis (Koolwijk et al, 
2001). 
 
2.2.1.4. Matrilysins 
 
Matrilysin (MMP-7) and endometase (MMP-26) are the smallest MMPs, lacking the hinge region 
and hemopexin domain, which is considered to restrict substrate specificity (Park et al, 2000). 
MMP-7 was originally identified as the small putative uterine metalloproteinase (PUMP), when 
screening for stromelysin-related genes (Muller et al, 1988). It cleaves in vitro elastin, the core 
protein of proteoglycans, fibronectin, entactin, laminin-1, gelatin, and serpins among others 
(Murphy et al, 1991b; Sires et al, 1993; Halpert et al, 1996). Unlike most other MMPs expressed or 
released only in response to injury, disease, or inflammation, matrilysin is expressed by noninjured, 
noninflamed exocrine and mucosal epithelium in many adult tissues. Specifically, matrilysin is 
produced by all skin and salivary glands, airway ciliated cells, and by the ductal or glandular 
epithelium of the pancreas, liver, breast, intestine, and urogenital tissues (Rodgers et al, 1994; 
Saarialho-Kere et al, 1995; Wilson et al, 1995). In addition, matrilysin is markedly upregulated by 
migrating epithelium in the injured airway (Dunsmore et al, 1998) and intestine (Saarialho-Kere et 
al, 1996), suggesting that a key role in the repair of epithelium other than that of skin. Repair of the 
injured trachea is, indeed, markedly impaired in MMP-7-deficient mice (Dunsmore et al, 1998). 
MMP-7 has been suggested to play a role in early stages of tumorigenesis (see Fingleton et al, 
1999). It is upregulated in many tumors, especially of epithelial origin, such as breast (Basset et al, 
1990), lung and upper respiratory tract (Muller et al, 1991), skin (Karelina et al, 1994), stomach and 
colon (Newell et al, 1994; McDonnell et al, 1991). In addition, intestinal tumorigenesis is reduced in 
MMP-7-deficient mice (Wilson et al, 1997). Interestingly, MMP-7 can also inhibit tumor 
angiogenesis by generating angiostatin (Patterson and Sang 1997), which has also been shown in 
vivo (Pozzi et al, 2000). 
 
MMP-26 was cloned from fetal (de Coignac et al, 2000), placenta (Uria and Lopez-Otin, 2000), and 
human endometrial tumor (Park et al, 2000) cDNAs. It efficiently cleaves fibrinogen and ECM 
proteins, including fibronectin, IV collagen, gelatin, vitronectin and α1-proteinase inhibitor (Park et 
al, 2000; Uria and Lopez-Otin, 2000; Marchenko et al, 2001a). MMP-26 has an unusual cysteine-
switch propeptide sequence and also a threonine residue adjacent to the Zn-binding site that has 
been defined as a specific feature of matrilysin. MMP-26 is detected in placenta and uterus and is 
also widely expressed in diverse tumor cell lines as well as in malignant tumors from different 
sources, including carcinomas of lung, prostate and breast by RT-PCR (Marchenko et al, 2001a). 
 
2.2.1.5. Membrane-type MMPs 
 
The first membrane-type MMP (MT1-MMP) was detected on the surface of invasive tumor cells in 
1994 (Sato et al) and altogether six distinct MT-MMPs have been found so far (MMP-14, MMP-15, 
MMP-16, MMP-17, MMP-24; MMP-25) (Takino et al, 1995; Will and Hinzmann, 1995; Puente et 
al, 1996; Llano et al, 1999; Pei 1999b). Their domain structure is similar to other MMPs, except for 
a transmembrane domain and cytoplasmic tail at the C-terminus. They also contain a furin-sensitive 
motif between the propeptide and catalytic domain, cleaving of which in trans-Golgi network leads 
to activation of MT-MMPs (Sato et al, 1996). MT4-MMP and MT6-MMP have a 
glycosylphosphatidylinositol (GPI)-anchor binding them to the cell surface and thus form their own 
subgroup in the MT-MMP family (Itoh et al, 1999; Kojima et al, 2000). Localization of MT-MMPs 
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at the cell surface implies that they might have a significant role in the regulation of cell-matrix 
interactions and activation of other MMPs. Indeed, MT1-, MT2- MT3-, MT5-, and MT6-MMP 
activate proMMP-2 (Will et al, 1996; Pei 1999a; Miyamori et al, 2000; Velasco et al, 2000), and 
MT1- and MT2-MMP also MMP-13 (Knäuper et al, 1996c). Furthermore, it has recently been 
shown that MT1-, MT2-, and MT3-MMP can degrade cell surface tissue transglutaminase (tTG) at 
the leading edge of motile cancer cells thus suggesting a novel regulatory function of membrane-
anchored MMPs in cancer cell adhesion and locomotion (Belkin et al, 2001). 
 
MT1-MMP (MMP-14) digests e.g., types I, II and III collagens, fibronectin, vitronectin, tenascin, 
nidogen, laminin-5, perlecan, proteoglycan core proteins, fibrin, α1-proteinase inhibitor and α2-
macroglobulin, as well as tumor TNF-α fusion protein (d'Ortho et al, 1997; Ohuchi et al, 1997; 
Hiraoka et al, 1998; Koshikawa et al, 2000). It seems to have an essential role in tumor cell invasion, 
mainly due to its ability to activate latent gelatinase A. The expression of MT1-MMP has been 
detected in tumor cells and adjacent stromal cells in a variety of human cancers, including head and 
neck, vulvar, lung, breast, colon, and liver carcinomas among others (Sato et al, 1994; Okada et al, 
1995; Harada et al, 1998; Johansson et al, 1999). 
 
MT2-MMP (MMP-15) is expressed in human brain, placenta and heart and in some cancers. It can 
degrade laminin, fibronectin and tenascin (Takino et al, 1995; d'Ortho et al, 1997). MT3-MMP is 
expressed in several human tissues, such as liver, placenta, colon, testis, intestine, pancreas, lung, 
kidney, and heart (Will et al, 1995). It degrades gelatin, casein, type II collagen, fibronectin, 
laminin-1, vitronectin, cartilage proteoglycan, α1-proteinase inhibitor, and α2-macroglobulin 
(Matsumoto et al, 1997; Shofuda et al, 1997; Shimada et al, 1999). The expression of MT3-MMP 
(MMP-16) is elevated after arterial injury, which also applies to MT1-MMP (Shofuda et al, 1998). 
 
MT4-MMP (MMP-17) is expressed in brain, leukocytes, colon, ovary and testis. It has also been 
found in breast carcinomas (Puente et al, 1996) and some carcinoma cell lines (Grant et al, 1999; 
Kajita et al, 1999). It degrades gelatin, fibrinogen and fibrin and has TNF-α convertase activity 
(Wang et al, 1999; English et al, 2000). MT5-MMP (MMP-24) is expressed in brain, kidney, 
pancreas and lung, and in brain tumors (Llano et al, 1999). Its expression is also upregulated in 
kidneys of diabetic patients and suggests a novel role for MT5-MMP in the pathogenesis of renal 
tubular atrophy (Romanic et al, 2001). Murine MT5-MMP is shed from the cell surface as a soluble 
proteinase (Pei 1999a). MT6-MMP (MMP-25) is specifically expressed by peripheral blood 
leukocytes (Pei 1999b) and some brain tumors (Velasco et al, 2000). It is able to cleave type IV 
collagen, gelatin, fibronectin and fibrin (English et al, 2001). 
 
2.2.1.6. Other MMPs 
 
MMP-19 has been cloned from mammary gland (Cossins et al, 1996) and liver (Pendas et al, 1997) 
and isolated also as an autoantigen from the inflamed rheumatoid synovium as RASI (Sedlacek et al, 
1998). It has a domain structure typical to MMPs, but it also contains a sequence of 36 residues in 
C-terminus lacking homology to any other MMP. MMP-19 is widely expressed in tissues, including 
placenta, lung, pancreas, ovary, spleen and intestine (Pendas et al, 1997) and also in acutely 
inflamed synovial tissue, especially in capillary endothelial cells, suggesting a role in angiogenesis 
(Kolb et al, 1999). MMP-19 is capable of degrading many components of the ECM and BM, e.g., 
type IV collagen, laminin, nidogen, tenascin-C, fibronectin, type I gelatin as well as aggrecan and 
cartilage oligomeric protein (COMP), but cannot activate any proMMPs (Stracke et al, 2000a; 
Stracke et al, 2000b). 
 
Enamelysin (MMP-20) is exclusively expressed in ameloblasts and odontoblasts of developing teeth 
(Llano et al, 1997). Human enamelysin is able to degrade amelogenin, the major protein component 
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of the enamel matrix, as well as aggrecan and COMP (Stracke et al, 2000b). On the basis of its 
degrading activity on amelogenin and its highly restricted expression to dental tissues, human 
enamelysin apparently plays a crucial role in tooth enamel formation. 
 
MMP-23, cloned from an ovary cDNA library (Velasco et al, 1999), is expressed mainly in ovary, 
testis and prostate and might have a specialized role in reproductive processes. It has a unique 
structure lacking structural features of diverse subclasses. It has a short prodomain and also 
shortened C-terminal domain showing no similarity to hemopexin. It lacks a classic cysteine switch, 
but it possesses two novel motifs: a cysteine array (CA) and a novel Ig-fold. Little is known about 
its biochemical function. In mouse homologue, it was shown to contain an RRRR motif, which 
regulates its secretion and activation. It might establish a third subclass of membrane-bound MMPs 
and, thus, a new subclass of the MMP superfamily (Pei et al, 2000). 
 
Epilysin (MMP-28) was cloned from testis and keratinocyte cDNA libraries (Lohi et al, 2001). It has 
a furin activation site and its splicing pattern differs from that of other MMP genes. By Northern 
analysis, it is expressed at high levels particularly in testis, but also in other tissues. It is also 
detected by immunohistochemistry in injured epidermis. According to Marchenko et al. (2001), lung 
is the main organ expressing MMP-28, and it is also expressed in a broad range of carcinomas as 
assessed by PCR (Marchenko and Strongin, 2001b). 
 
2.2.2. Regulation of MMPs 
 
MMPs are highly regulated, with both secretion and activity levels under tight control. In general, in 
normal tissue, MMPs are expressed at very low levels, if at all, but their production and activation is 
rapidly induced when active tissue remodeling is needed (see Nagase and Woessner, 1999). MMP 
proteins are transcribed and secreted by the constitutive secretory pathway, except in the case of 
immune cells, such as macrophages and neutrophils, where MMPs can be stored in, and released 
from, secretory granules (MMP-8 and –9). In addition, MMP-7 is constitutively expressed in the 
ductal epithelium of exocrine glands (Saarialho-Kere et al, 1995). Regulation occurs at multiple 
levels, including transcription, modulation of mRNA half-life, secretion, localization, zymogen 
activation and inhibition of proteolytic activity. MMPs have natural inhibitors, tissue inhibitors of 
metalloproteinases (TIMPs), and certain non-specific proteinase inhibitors, such as α2-
macroglobulin. 
 
2.2.2.1. Transcriptional regulation 
 
At transcriptional level, a variety of cytokines and growth factors (e.g. TNF-α, EGF, bFGF, IL-1, 
PDGF, IL-6 and TGF-β) induce production of MMPs depending on the situation and cell type. Also 
oncogenes, hormones and various chemical agents (e.g. phorbol esters) as well as cell-cell and cell-
matrix interactions can induce or repress the expression of MMPs (see Nagase and Woessner, 
1999). 
 
Promoters of MMPs show remarkable conservation of regulatory elements (see Westermarck and 
Kähäri, 1999). Extracellular stimuli regulate MMP activity through AP-1 (activator protein-1) 
binding site, which is situated in the proximal promoter approximately at position -70 bp, with 
regard to the transcription initiation site in inducible MMP genes (MMPs -1, -3, -7, -9, -10, -12, -13, 
and -19) (Figure 4). Another AP-1 site is found in the promoters of MMP-1, MMP-3 and MMP-9. 
AP-1 site binds dimeric transcription factors of the Jun and Fos families, which stimulate the 
transcription of the MMP genes. The expression of the transcription factors are activated by 
extracellular signals through three distinct mitogen activated protein kinase (MAPK) pathways, i.e. 
extracellular signal-regulated kinase (ERK1,2), stress activated protein kinase/Jun N-terminal 
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kinases (SAPK/JNK), and p38. In general, ERK1,2 cascade is activated by mitogenic signals, while 
SAPK/JNKs and p38 are activated by cytokines (TNF, IL-1) and cellular stress, such as UV light 
(Karin et al, 1997). MMP-2, MMP-11, MMP-28 and MT1-MMP genes do not have an AP-1 site in 
their promoters. The 5'-flanking sequence of the MT1-MMP gene contains putative regulatory 
elements, including one SP-1 site and four CCAAT-boxes, whereas there is no TATA-box (Lohi et 
al, 2000). The MMP-28 promoter has distinctive structural and functional features including GT-
box, which dramatically reduces the transcriptional activity of the MMP-28 gene. Also SP-1 and SP-
3 are potential regulators of it (Illman et al, 2001). MMP-11 is transcriptionally activated only by 
retinoic acid or by stromal cell interactions with tumor cells (Anglard et al, 1995; Ahmad et al, 
1997). 
 
Although the importance of AP-1 site is undeniable, transcriptional activity usually depends on its 
interaction with several other cis-acting sequences located throughout the promoter (Figure 4). 
Multiple polyomavirus enhancer A-binding protein-3 (PEA-3) sites are present in all the promoters 
except MMP-2. They are located adjacent to at least one AP-1 element, except in MMP-12 (Figure 
4) and bind members of the ETS family of transcription factors (Wasylyk et al, 1991). Individual 
AP-1 and PEA3 sites often play distinct roles in basal and induced transcription, probably due to the 
function of the specific transcription factors binding to these sites. ETS and AP-1 factors can 
synergistically activate MMP transcription, and other transcription factors often contribute, 
particularly in response to growth factors and cytokines. Besides MMP expression, collaboration 
between ETS and AP-1 has been shown to regulate the promoters of many genes involved in tumor 
progression (Denhardt 1996). The expression of ETS-1 colocalizes with several MMPs at the 
invasive edge of many tumors; ETS-1 is also expressed during tumor angiogenesis (Wernert et al, 
1992). AP-1 site plays a major role in the repression of MMPs by TGF-β, retinoids and 
glucocorticoids (Benbow et al, 1997). A TGF-β-inhibitory element (TIE) has been described in 
some promoters, and, at least in MMP-3 promoter, it mediates TGF-β repression (see Vincenti 
2001). 
 
Induction of MMP-12 in macrophages by cytokines and growth factors (IL-1, TNF-α, M-CSF, 
VEGF, PDGF-BB), as well as its inhibition by TGF-β1, depended on signaling through an AP-1 site 
at -81 base pairs. The inhibitory effect of TGF-β1 on MMP-12 was dependent on Smad3 
transcription factor (Feinberg et al, 2000) (Figure 4). Furthermore, AP-1 site is critical for the 
induction of MMP-12 promoter activity by GM-CSF. AP-1 binding activity was increased by GM-
CSF treatment and the AP-1 complex induced by GM-CSF consisted of multiple Jun and Fos 
isoforms (Wu et al, 2000). MMP-12 gene activity can, interestingly, be regulated in an allele-
specific manner. A common functional polymorphism within the MMP-12 promoter influences the 
binding affinity of AP-1 and, thus, coronary artery luminal dimensions in diabetic patients with 
manifest coronary artery disease (Jormsjo et al, 2000). 
 
Both AP-1 and PEA3 sequences are required for the induction of MMP-7 by tumor promoter 12-O-
tetradecanoylphordol-13-acetate (TPA) and EGF (Figure 4). In addition, induction of MMP-7 
expression and activity by Ki-ras oncogene is mediated through AP-1. Interestingly, ras mutations 
are associated with colon tumor progression, as is MMP-7. MMP-7 can be both upregulated and 
downregulated by TGF-β and has several TIE elements in its promoter (Figure 4) (Wilson and 
Matrisian, 1998). MMP-7 is also a target gene for β-catenin-Tcf transcription complex, whose 
activity is thought to play a crucial role in the initiation of intestinal tumorigenesis, and it functions 
in co-operation with PEA3 and AP-1 factors (Crawford et al, 2001). MMP-10 is responsive for 
various growth factors, like TGF-α, EGF, KGF, TNF-α and TGF-β1, as well as phorbol ester in 
keratinocytes (Windsor et al, 1993; Madlener et al, 1996), but functional studies at the 
transcriptional level have not been performed. 
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   Figure 4. Regulatory elements of promoter regions of MMP-7, -10, and –12 (modified from Westermarck 
   and Kähäri, 1999). LBP, leader binding protein; SBE, STAT binding element; TCF, Tcf binding site; TRF, 
   octamer binding protein. 
 
2.2.2.2. Proenzyme activation 
 
In most cases the activity of MMPs is controlled extracellularly: they are secreted in an inactive, 
latent form that requires the removal of the prodomain to attain the catalytically active state. MMP-
11, MMP-28 and MT-MMPs are activated intracellularly by Golgi-associated furin-like proteases. 
MMP-23 is both activated and released from the cell surface by a single cleavage (Pei et al, 2000). 
The latency of MMPs is dependent on cysteine switch (Springman et al, 1990). The highly 
conserved cysteine residue in the prodomain binds covalently to the Zinc-ion in the catalytic domain, 
and this interaction has to be disrupted in order to activate proMMPs (Nagase and Woessner, 1999). 
Various compounds, e.g. organomercurials (APMA), SH-reactive agents, reactive oxygen and 
detergents can react with this cystein and convert it to a nonbinding form (Springman et al, 1990; 
Nagase and Woessner, 1999). 
 
Secreted proMMPs can be activated in vitro with plasmin, trypsin, kallikrein, chymase, and mast cell 
tryptase. MMPs can also activate other MMPs (see Table I). A classical example is the activation of 
proMMP-2 with MT1-MMP, which starts with TIMP-2 and MT1-MMP forming a receptor complex 
to the cell surface. TIMP-2 has a free C-tail, which binds proMMP-2, and then TIMP-2-free MT1-
MMP can activate proMMP-2 (Zucker et al, 1998). At low levels TIMP-2, thus, enhances the 
activation process, whereas at high levels it inhibits MMP-2 activation (see Seiki 1999). Also TIMP-
4 can form complex with proMMP-2, while TIMP-1 forms complex with proMMP-9, and TIMP-3 
with both proMMPs-2 and -9 (Goldberg et al, 1989; Bigg et al, 1997; Butler et al, 1999). The 
uPa/plasmin system, as well as other proteinases, activate proMMPs, including MMPs-2, -9, and -
12, in many physiological situations (Carmeliet et al, 1997; Mazzieri et al, 1997). These activation 
cascades between MMPs and other proteinases form complex networks in regulating tissue 
proteolysis. 
 
2.2.2.3. Inhibitors of MMPs 
 
MMP activity is further modulated through interactions with their natural inhibitors, the specific 
tissue inhibitors of matrix-metalloproteinases (TIMPs) (Edwards et al, 1996; Gomez et al, 1997). In 
addition, serine protease inhibitors (serpins), which include α1-antitrypsin and plasminogen 
activator inhibitors (PAI)-1 and –2, control general proteolytic activity, including MMPs, in tissues. 
Also non-specific serum proteinase inhibitors (e.g. α-macroglobulin) can inhibit the proteolytic 
activity of MMPs. α-macroglobulin is abundant in many human tissues and is important in 
inhibiting MMP activity in serum and body fluids. It can also inhibit serine-, cysteine-, and aspartate 
proteinases (Birkedal-Hansen et al, 1993). Due to the role of MMPs in many pathological 
conditions, various chemical inhibitors have also been synthesized in order to use them as 
therapeutic agents (Brown et al, 1999) (see chapter 2.3.4.3. at page 35). 
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Four TIMP family members have been described to date (TIMPs-1, -2, -3, and -4), most of which 
are capable of binding and inhibiting the activity of all the members of the MMP family. (Edwards 
et al, 1996; Gomez et al, 1997). In general, TIMPs can inhibit the activity of all MMPs in vitro, 
except MT1-MMP and MT3-MMP, which are not inhibited by TIMP-1 (Will et al, 1996; Shimada 
et al, 1999). The tertiary structure of TIMPs is very similar. However, TIMPs demonstrate 
differences in tissue distribution, as well as in their ability to form complexes with the inactive form 
of MMP and, thus, the ability to control MMP activation. The N-terminus is necessary for MMP 
inhibition (Murphy et al, 1991a; Langton et al, 1998) while the C-terminal end affects their 
specificity (Goldberg et al, 1992; Ogata et al, 1995; Bigg et al, 1997). The mechanism involves 
forming non-covalent stoichiometric complexes with the zinc-binding site of the active form of 
MMPs (Gomis-Rüth et al, 1997). Furthermore, TIMPs can inhibit the activation of many proMMPs 
and various TIMPs have preferential inhibitory capabilities against different proMMPs. For 
instance, TIMP-1 preferentially forms complex with proMMP-9, while TIMP-2 and TIMP-4 
reduced proMMP-2 activation by MT1-MMP. TIMP-4 also binds to MT1-MMP inhibiting its 
autocatalytic processing (Gomez et al, 1997; Hernandez-Barrantes et al, 2001). 
 
Except for TIMP-3, which is bound to ECM (Leco et al, 1994), TIMPs are present in a soluble form 
in most tissues and body fluids (Gomez et al, 1997) and expressed by a variety of cell types. The 
latest member of the TIMP family, TIMP-4, is mainly expressed in heart (Greene et al, 1996), 
suggesting a tissue-specific function. The expression of TIMP-1 and TIMP-3 is upegulated by 
various growth factors and cytokines, including TGF-β, EGF, TNF-α, ILs, retinoids, and 
glucocorticoids, while the expression of TIMP-2 is mainly constitutive (Birkedal-Hansen 1995). 
 
TIMPs play an important role in many biological processes, including fetal development, arthritis, 
angiogenesis and cancer. An imbalance between TIMP and MMP activities is considered to result in 
excessive degradation of ECM components in tumor invasion and metastasis, and their reciprocal 
expression levels have been assessed for prognostic significance (Birkedal-Hansen 1995). Besides 
antitumor activity, TIMPs may also have growth promoting activity in an MMP-independent fashion 
(Henriet et al, 1999). Other functions of TIMPs include matrix binding, inhibition of angiogenesis 
and the induction of apoptosis (Brew et al, 2000). The balance between various TIMPs may also be 
a critical factor in determining the degradative potential of cells in normal and pathological 
conditions. 
 
2.2.3. MMPs in development 
 
Embryonic development requires an accurate coordination of programs for growth, differentiation, 
ECM formation and angiogenesis. These processes are modulated by a diverse group of 
macromolecules, including ECM glycoproteins, their receptors, i.e. integrins, and ECM-degrading 
enzymes as well as their inhibitors. Studies suggest that, besides degrading ECM components, 
MMPs appear to regulate many fundamental cellular processes of development, including 
morphogenesis, apoptosis, cell migration, proliferation and invasion. They are involved e.g., in 
ovulation, embryonic growth, trophoblast invasion, and the development of the skeleton and organs 
(see Birkedal-Hansen et al, 1993; Werb and Chin, 1998; Werb et al, 1999). Tissue morphogenesis 
depends on specific movements of the cells which sometimes have to migrate over long distances. 
Studies have implicated MMPs in the migration of a variety of epithelial, mesenchymal, and 
neuronal cells either through the ECM or on a specific substrate. Organ cultures show that MMPs 
are also involved in altering ECM, permitting invasion, selection of branch points, and regulation of 
epithelial-to-mesenchymal transition during branching morphogenesis. Interaction between ECM 
components and cell surface molecules regulate cell behavior, and MMPs affect cell survival and 
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proliferation both positively and negatively by regulating survival signals generated by specific 
adhesive events (Vu and Werb, 2000). 
 
MMPs in human development: The role of MMPs in human development has mainly been 
elucidated by studying their expression in specific tissues. MMP-1 has been detected in developing 
fetal skin from 6 to 20 weeks. It is associated with the development of interfollicular epidermis, the 
collagenous dermis, and the development of nerves and hair follicles (McGowan et al, 1994). It also 
participates in blood vessel development in fetal skin (Karelina et al, 1995). MMP-2 is involved in 
appendageal development and contributes to the remodeling of the BM zone during fetal skin 
morphogenesis. The absence of type VII collagen, which is the major component of anchoring 
fibrils, correlated directly with the presence of MMP-2 (Karelina et al, 2000). Expression of MMPs 
has also been demonstrated during intrahepatic bile duct development, where MMP-2, -3, and -9 
were expressed only in the ductal plate, while MMP-1 was also present in migrating biliary cells and 
immature bile ducts (Terada et al, 1995). Furthermore, MMP-1, -2, -7 and -13 proteins were 
localized in the early human liver anlage already at the 6th gestational week in different cell types at 
different time points. MMP-13 was found exclusively in hematopoietic cells, as was MMP-7 from 
the 7th week onward (Quondamatteo et al, 1999). By RT-PCR, MT1-MMP was detected in fetal 
membranes (Fortunato et al, 1998). MMP-13 mRNA has been detected in hypertrophic 
chondrocytes in developing human bone beginning at week 10 and osteoblasts and fibroblasts in 
calvarial bone at week 16 (Johansson et al, 1997b; Ståhle-Bäckdahl et al, 1997). Also MMP-10 
protein has been localized to chondrocytes of the growth plate in the fetal rib, while MMP-3 was in 
osteocytes in the surrounding fibrous tissue. They were both also expressed by osteoblasts at sites of 
bone formation, and MMP-10 in osteoclasts as well (Bord et al, 1998). MMP-1, MMP-2, and MMP-
9 were expressed in developing human fetal testis and ovary (Robinson et al, 2001). Obviously, it is 
crucial that MMPs and their inhibitors, TIMPs, function coordinately during various stages of 
development. Expression of TIMP-3 mRNA has been detected in developing bone, kidney, and in 
mesenchymal cells, whereas TIMP-1 was only detected in osteoblasts of developing bone (Airola et 
al, 1998). All four TIMPs have been detected in ovary and testis (Robinson et al, 2001). 
 
The skeleton develops either by intramembranous or endochondral ossification (flat bones of the 
skull or long bones and spine, respectively). Endochondral ossification is a process where avascular 
tissue (cartilage) is turned into highly vascularized bone tissue. Chondrocytes proliferate and mature 
to form columns of hypertrophic cartilage which is then resorbed and replaced by bone matrix. 
Ossification begins with the invasion of calcified hypertrophic cartilage by capillaries. Terminal 
hypertrophic chondrocytes undergo apoptosis, cartilage matrix is degraded, and osteoblasts form the 
trabecular bones, which are subsequently remodelled by osteoclasts. Cartilage is normally highly 
resistant to vascularization, except hypertrophic cartilage during this process (Werb et al, 1999). 
Thus, angiogenesis requires the invasion of endothelial cells and localized proteolytic degradation of 
ECM. Transgenic mice have proven useful when determining the contribution of individual MMPs 
to biological processes, including development (Shapiro et al, 1998). Two MMPs have been 
implicated to be particularly important in bone development: MMP-9 and MT1-MMP. In MMP-9-
deficient mice, vascular invasion was impeded, which was coupled with a delay in apoptosis of 
hypertrophic chondrocytes and ossification of hypertrophic cartilage. As a result, long bones were 
shorter than in control animals (Vu et al, 1998). It has been suggested that MMP-9 would regulate 
the release of an angiogenic factor from hypertrophic cartilage. Thus, the lack of MMP-9 would lead 
to decrease in vascular invasion. MMP-9 may have also other functions, such as regulation of 
apoptosis or resorption of cartilage (Vu and Werb, 2000). MT1-MMP knock-out mice also have 
severe defects in skeletal development and angiogenesis which are different from that in MMP-9-
null mice (Holmbeck et al, 1999; Zhou et al, 2000). The mice have craniofacial dysmorphism, 
arthritis, osteopenia, dwarfism, and fibrosis of soft tissues due to inadequate collagenolytic activity 
that is essential for modeling of skeletal and extraskeletal connective tissues. The shortening of 
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bones is a consequence of impaired endochondral ossification. The defect in angiogenesis is not 
probably restricted to cartilage alone. 
 
Developmental defects resulting from the inactivation of other MMP genes have not been apparent. 
Many processes that are affected in vitro by MMPs do not seem to be affected by the lack of 
relevant MMP in vivo. For example, kidney development requires MMP-9 and MT1-MMP in vitro, 
but in MMP-9 or MT1-MMP knock-out mice kidney development is not affected (Vu and Werb, 
2000). There may be compensatory mechanisms in vivo allowing only defects where individual 
MMP plays a crucial function to be seen. MMPs have overlapping substrate specificities and are 
simultaneously expressed in various developmental stages. Furthermore, the mechanisms of relevant 
MMPs are difficult to understand by looking at only the end result of its deficiency, since these 
events usually include a very complex interplay between many cellular processes (Shapiro et al, 
1998; Vu and Werb, 2000). 
 
2.3. PROTEOLYSIS IN CANCER 
 
2.3.1. Tumor invasion and metastasis 
 
Tumorigenesis is a complex, multistage process, where a normal cell undergoes genetic changes 
resulting in the ability to invade, and spread to, distant sites of the body. When a tumor cell acquires 
this ability it is called “malignant“. Invasive growth is associated with excessive degradation of 
various matrix structures. Interactions between the tumor and its microenvironment result in the 
production of proteolytic enzymes crucial for this process. The ability to form tumors at distant sites 
(metastasis, secondary lesion) is characteristic of highly malignant tumors with poor clinical 
outcome. The loss of an intact BM as the first barrier is, therefore, the initial step of tumor invasion 
(Figure 5). In order for invasion and metastasis to occur, a cell or group of cells must be able to 
detach from the primary tumor, invade through BM and interstitial ECM. The tumor cell enters the 
circulation either through lymphatic vessels or through blood vessels in a process called 
intravasation. It must survive the circulation to arrest at the distant capillary bed. In order for the 
tumor to establish itself in a distant place, it must repeat the steps in reverse. This process of 
extravasation requires the tumor cell to leave the circulation, adhere to subendothelial BM, attain 
access into the organ parenchyma and invade through matrix again. Furthermore, it has to respond to 
growth factors, proliferate as a secondary colony, induce angiogenesis and evade host defences (see 
Ellis and Fidler, 1996; McCawley and Matrisian, 2000). 
 
2.3.2. Tumor angiogenesis 
 
In the adult organism, angiogenesis, i.e. forming of new blood vessels from existing ones, is 
normally limited to events of tissue repair/remodeling such as that occurring during menstruation, 
mammary gland involution, wound healing and inflammation. Angiogenesis is a complicated 
process that requires: 1) degradation of the BM and ECM surrounding blood vessels; 2) chemotaxis 
of endothelial cells toward an angiogenic stimulus; 3) proliferation of endothelial cells; and 4) 
remodeling of the BM and synthesis of new matrix components as the new blood vessel forms (Ellis 
and Fidler, 1996). It is now well established that in order to maintain continuous growth, invasion 
and formation of metastases, malignant tumors depend critically on neovascularization, which 
enables nutrient and oxygen supply (Folkman 1995). The ability of the tumor to promote 
angiogenesis is thought to be one of the early events in the transition of a tumor from pre-neoplastic 
stage to neoplastic phenotype. Pathological studies of various human cancers have also shown a 
correlation between an increased number of tumor blood vessels and poor prognosis (see Weidner 
1995). New blood vessels penetrating the tumor are frequent sites of tumor cell entry to the 
circulation. Metastatic cells themselves must again undergo angiogenesis to grow a clinically 
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detectable size. The switch into angiogenic phenotype depends on a net balance between positive 
and negative regulators of blood vessel growth. Therefore, the increased production of angiogenic 
stimulators, such as angiogenin, VEGF or bFGF, is not sufficient for angiogenic phenotype, but 
inhibitors (e.g. thrombospondin-1, angiostatin, endostatin) must be decreased as well. It is obvious 
that the understanding of the cellular events and molecular regulation of angiogenesis has 
tremendous clinical implications (see Folkman 1995; Hanahan and Folkman, 1996). 
 
 
  Figure 5. Multiple stages of tumor progression (modified from Ellis and Fidler, 1996). 
 
2.3.3. Stromal contribution to tumorigenesis 
 
Interactions of tumor cells with stromal components are important for tumorigenesis (see Iozzo 
1995). As tumor progresses from a hyperplastic, premalignant stage through angiogenic switch to an 
invasive metastatic cancer, there is constant communication between tumor cells and the 
surrounding stromal components, including fibroblasts, endothelial cells, inflammatory cells and 
structural matrix components (see McCawley and Matrisian, 2001). Alterations in the stroma of 
malignant tumors involve the synthesis and breakdown of ECM components, as well as changes in 
cell behavior, adhesion and migration. The reactions in tumor stroma are often viewed as a non-
specific host response in order to slow down tumor progression. Stromal fibroblasts also participate 
in the degradation of ECM by secreting matrix degrading proteases as well as their activators 
(Wernert 1997). 
 
Inflammation is a protective reaction elicited by the host in response to infection, injury or tissue 
damage. Under normal physiological conditions, this response serves to eliminate pathogens and 
initiate repair. Many malignancies may also arise from the areas of infection and inflammation as 
part of the normal host response, and as such “tumors are often viewed as wounds that do not heal“ 
(Wernert 1997). The inflammatory component of a developing neoplasm includes a diverse 
leukocyte population, e.g., macrophages, neutrophils, eosinophils, and mast cells, all of which are 
variably loaded with different cytokines and cytotoxic mediators including serine-, cysteine-, and 
metalloproteinases, as well as soluble mediators of cell killing, such as TNF-α, ILs and IFNs (see 
Coussens et al, 2001). After activation, mast cells can release stored and newly synthesized 
inflammatory mediators, including factors known to enhance angiogenic phenotype such as heparin, 
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metallo- and serine proteinases, and various growth factors (bFGF, VEGF) (Coussens et al, 1999). 
Macrophages also have the potential to mediate tumor cytotoxicity and to stimulate antitumor 
lymphocytes. Tumor cells can benefit from the activities of tumor-associated macrophages (TAMs), 
which can produce factors directly promoting tumor growth (like IL-1 and PDGF). Furthermore, 
proteases secreted by these macrophages degrade the surrounding tissue and facilitate tumor cell 
expansion and invasion. TAMs can also promote angiogenesis by secreting potent angiogenic 
proteases, cytokines, and growth factors, like bFGF, VEGF and TNF-α, or inhibit angiogenesis by 
producing inhibitors (like angiostatin or GM-CSF). Macrophages are, in fact, expected to influence 
every stage of angiogenesis (Wahl and Kleinman, 1998; Joseph and Isaacs1998; Ono et al, 1999). 
 
2.3.4. MMPs in tumor progression 
 
The initial observation of the importance of MMPs in cancer biology was that tumor cells with the 
ability to penetrate the surrounding tissue correlated with increased MMP levels (Liotta et al, 1980). 
Subsequently, many MMP family members have been isolated from tumor cell lines or found to be 
overexpressed in various tumor tissues, especially the malignant tumor front. They are also regulated 
both by oncogenes and growth factors involved in cancer progression (Crawford et al, 1996). The 
early hypothesis was that tumors expressed MMPs to make holes in the ECM in order to allow the 
movement of tumor cells across the BM, thereby initiating the development of metastasis. Although 
MMPs are typically present at the invasive front, MMP levels can, however, be elevated already in 
the early stages of tumor progression. Recent work extends the role of MMPs to multiple stages of 
tumor progression, including growth, cell migration and angiogenesis (McCawley and Matrisian, 
2000). 
 
MMPs enable tumor angiogenesis as they allow endothelial cells to invade through BMs to form 
new blood vessels. They also regulate endothelial cell attachment, proliferation, migration and 
growth, either directly or by the release of growth factors. The importance of MMPs in angiogenesis 
is substantiated by the fact that synthetic and endogenous MMP inhibitors also reduce angiogenic 
responses (see Stetler-Stevenson 1999). For example, a peptide called PEX prevents MMP-2 
binding to the integrin αvβ3, which reduces angiogenesis and tumor growth in a model system 
(Brooks et al, 1998). Furthermore, MMP-deficient mice (MMP-2, -9 and -14) all demonstrate 
defective angiogenesis (Itoh et al, 1998; Vu et al, 1998; Zhou et al, 2000). Endothelial cells can 
produce at least MMP-1, -2, -9, -19 and MT1-MMP, but then again, inflammatory cells and 
fibroblasts express many MMPs and also contribute to angiogenic phenotype. For instance, 
infiltration by mast cells and activation of MMP-9 coincides with the ’angiogenic switch’ in 
premalignant lesions during squamous epithelial carcinogenesis (Coussens et al, 1999). MMP-9 
promotes tumor angiogenesis in other mouse tumor models as well (Bergers et al, 2000b; Yu and 
Stamenkovich, 2000). The crucial role of MMP-2 and MT1-MMP in angiogenesis has perhaps been 
studied the most (see Foda and Zucker, 2001). 
 
Additional evidence for the critical role of MMPs in tumorigenesis has been provided with 
transgenic and knock-out mice. For instance, mice lacking MMP-7 show reduced intestinal 
tumorigenesis (Wilson et al, 1997), and besides defective angiogenesis, MMP-2 knock-out mice 
exhibit reduced tumor progression (Itoh et al, 1998). In addition, chemical mutagenesis results in 
decreased tumorigenesis in MMP-11-deficient mice (Masson et al, 1998). Mice lacking MMP-9 
show reduced keratinocyte hyperproliferation at all neoplastic stages and a decreased incidence of 
invasive tumors during skin carcinogenesis (Coussens et al, 2000). Furthermore, overexpression of 
MMP-3 and MMP-7 in transgenic mice led to enhanced tumorigenesis in breast cancer model 
(Rudolph-Owen et al, 1998; Sternlicht et al, 1999). Similarly, overexpression of MMP-1 enhanced 
tumor formation in a chemically induced model on skin carcinogenesis (D'Armiento et al, 1995). 
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Besides the classic role of MMPs in the degradation of ECM in tumorigenesis, new roles are 
emerging which make the contribution of MMPs much more complex than initially thought. As 
ECM is not static, cells receive clues from their environment through attachments to the matrix and 
thus respond to changes in their environment. MMP activity, either directly or indirectly, is vital for 
this process. For instance, MMPs cleave receptors involved in cell adhesion, unmask cryptic sites of 
interaction, activate growth factors, and act on ECM components or other proteins to uncover 
hidden biologic activities which can affect cell proliferation, migration and angiogenesis (Figure 6). 
MMPs are thereby involved in creating an environment suitable for tumor progression (see Bergers 
and Coussens, 2000a; McCawley and Matrisian, 2001; Stetler-Stevenson et al, 2001). Furthermore, 
MMP-mediated degradation of ECM components may generate also inhibitors of angiogenesis and 
cell growth. MMPs are now thought to be the most important proteases responsible for generating 
the potent angiogenesis inhibitor angiostatin, which is an NH2-terminal fragment of plasminogen 
and effectively inhibits endothelial cell proliferation. MMPs capable of cleaving angiostatin are 
MMP-3, -7, -9 and -12, of which MMP-12 is the most potent (Patterson and Sang, 1997; Cornelius 
et al, 1998). 
 
 
Figure 6. Expanded view of MMP-mediated proteolysis (modified from Bergers and Coussens, 2000). MMPs can 
cleave: reseptors (or proteins) involved in cell-matrix or cell-cell adhesion, latent cell surface ligands, matrix proteins 
generating new bioactive fragments and sequestered growth factors and inhibitors. Through these actions MMPs 
regulate, for example, angiogenesis, cell proliferation, migration and apoptosis. 
 
2.3.4.1. MMP expression in tumors 
 
MMP expression patterns show that, in addition to tumor cells, also surrounding stromal cells and 
inflammatory cells involved in cancer progression can overexpress various MMPs and complement 
the proteolytic capacities of one another. The stromal expression was originally reported by Basset 
et al. (1990), who noticed that stromal fibroblasts were responsible for producing MMP -11 in breast 
cancer. Since then, it has been shown by in situ hybridization that stromal expression of MMPs is, in 
fact, more common than tumor cell expression. For example, MMP-1, -2, -3, -9, -11, and -14 
mRNAs are mainly expressed by stromal fibroblasts in the vicinity of tumor cells in many human 
cancers, including breast, colorectal, lung, prostate and ovarian cancers (see Nelson et al, 2000). 
There are exceptions, such as MMP-7, which is mainly expressed in tumor cells. Also MMP-13 is 
usually expressed in tumor cells, and often at the invading front (Johansson et al, 1997c; Johansson 
et al, 1999). In breast cancer, most MMPs, namely MMP-1, MMP-2, MMP-3, MMP-11 and MT1-
MMP were expressed by fibroblasts in the tumor stroma, while only MMP-7 and MMP-13 were 
expressed by tumor cells. MMP-9 localized to endothelial cells and MMP-12 to macrophages 
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(Heppner et al, 1996). Interestingly, in a mouse model of skin carcinogenesis, MMP-9 supplied by 
reactive stromal cells (macrophages, neutrophils and mast cells) contributes to skin carcinogenesis, 
and inflammatory cells thus act as “coconspirators” in cancer and may actually represent a useful 
target for anti-cancer therapy (Coussens et al, 2000). Tumor cells can induce MMP expression either 
directly or by secreting soluble factors belonging to the immunoglobulin superfamily, called 
EMMPRINs, that induce MMP expression in stromal fibroblasts. To date only MMPs-1, -2, and -3 
have, however, been shown to be induced by EMMPRINs (Kataoka et al, 1993; Biswas et al, 1995). 
 
MMP-9 mRNA has been demonstrated in inflammatory cells, but the protein can still be detected in 
tumor cells (Monsky et al, 1993). The same phenomenon has been observed with MMP-2 mRNA, 
as it is mainly expressed by stromal cells at the invading tumor front, but the protein localizes to 
tumor cells, e.g., in breast, colon and skin cancers, as well as hepatocellular and pancreatic 
adenocarcinomas (Pyke et al, 1992; Pyke et al, 1993; Heppner et al, 1996; Määttä et al, 2000). This 
discrepancy may be due to the fact that the half-life of MMP mRNA and the efficiency of 
translation differ between stromal and neoplastic cells. Alternatively, tumor cells can bind stromal-
secreted MMPs (Brooks et al, 1998; Yu and Stamenkovich, 2000). Similar discrepancy in MT1-
MMP mRNA and protein localization has been shown in head and neck carcinoma, for example. 
Thus, it is possible that MT1-MMP protein produced by stromal cells migrates onto tumor cell 
surfaces, as MMP-2 does (Yoshizaki et al, 1997). ProMMP-2 secreted by stromal fibroblasts could 
then be activated after binding to MT1-MMP at the tumor cell surface as originally reported by Sato 
et al. (1994). Results on MT1-MMP are somewhat conflicting, since expression of MT1-MMP has 
been reported in stromal cells and in neoplastic epithelium, or both, e.g. in colon, lung, breast, head 
and neck, gastric, pancreatic, and hepatocellular carcinoma (Nomura et al, 1995; Okada et al, 1995; 
Polette et al, 1996; Mori et al, 1997; Harada et al, 1998; Imamura et al, 1998; Shimada et al, 2000) . 
 
The expression patterns (mRNA and proteins) of both MMPs and TIMPs, as well as their 
combinations, have been studied as prognostic indicators of clinical outcome in many cancers. 
These studies suggest that MMPs and TIMPs may not only be good targets for cancer therapy but 
may also have clinical value in identifying subgroups of patients with an increased risk for 
recurrence. Generally, the expression of high levels of multiple MMP family members correlates 
positively with tumor aggressiveness, including increased invasive capacity, metastasis and poor 
patient survival. A direct correlation between MMP expression and the invasive phenotype of 
human tumors has been detected, for instance, in lung, prostate, stomach, colon, breast, ovary, and 
oral squamous cell cancers, where many MMPs are expressed at high levels (see Stetler-Stevenson 
et al, 1996). However, there is no single MMP consistently overexpressed in every tumor type, or a 
consistent pattern of MMP expression across a variety of human cancers, which reflects the 
heterogeneity of tumors and differential expression of MMPs during tumor progression. At least 
MMP-1, MMP-2, MMP-7, MMP-9, MMP-11 and MT1-MMP are frequently overexpressed in many 
human tumors (see Nelson et al, 2000; Foda and Zucker, 2001; Stetler-Stevenson and Yu, 2001). 
 
2.3.4.2. MMPs in skin cancer and other epithelial tumors 
 
Solar elastosis and solar keratosis: Prolonged exposure of skin to sun light leads to dermal 
photoageing characterized by alterations in the composition of the dermal matrix, such as an 
increase in the amounts of elastin, fibrillin and versican (Bernstein et al, 1994; Bernstein et al, 
1995b) and reduced amounts of type I collagen and decorin (Bernstein et al, 1995a; Bernstein et al, 
1996b). The term elastosis indicates an increased amount of connective tissue fiber in the upper 
reticular dermis. The elastoses are a reaction to prolonged exposure to the sun and/or heat over many 
years. Those affected are generally elderly people who have little protective pigment or people who 
have been overexposed to the sun during their lives. In patients with clinically evident solar 
elastosis, staining reveals degeneration of collagen in the upper dermis. The elastotic material 
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usually consists of aggregates of thick bands, and in areas of severe solar degeneration it may extend 
into lower portions of the dermis (see Lever and Schaumburg-Lever 1990b). 
 
Solar keratoses (actinic keratoses) represent in situ carcinoma with varying degrees of epidermal 
atypia or dysplasias and are very common in elderly people. Excessive exposure to sunlight over 
many years and inadequate protection against it are essential predisposing factors. Histologically, 
actinic keratoses are usually well-separated islands of abnormal keratinocytes with overlying 
parakeratosis. The upper dermis usually shows chronic inflammatory infiltrate. Unlike BCCs, the 
majority of SCCs in light-exposed areas may arise from pre-existing solar keratoses but they rarely 
metastasize (Marks et al, 1988; Lever and Schaumburg-Lever, 1990c). 
 
Several members of the MMP family have been implicated in photoageing. UVA induced the 
expression of MMP-1 by dermal fibroblasts in vivo and the expression of MMP-1, -2, and -3 in 
culture (Scharffetter et al, 1991). UVB induced the expression of MMP-1, -3, and -9 in normal 
human epidermis in vivo (Koivukangas et al, 1994; Fisher et al, 1996). These MMPs may take part 
in the degradation of type I collagen seen in chronically photoaged skin (Bernstein et al, 1996a; 
Fisher and Voorhees, 1998). Of MMPs-1, -2, -3 and -13 only MMP-1 was expressed in actinic 
keratoses by in situ hybridization (Airola et al, 1997; Tsukifuji et al, 1999). 
 
Basal cell carcinoma (BCC) is the most common malignancy in humans (Caucasian populations) 
especially in the elderly population (see Ramsey 2001). It is usually slow growing and rarely 
metastasizes but can cause significant local destruction and disfigurement if treated inadequately. 
With proper therapy, the prognosis is excellent and death extremely rare. BCC is considered to arise 
from multipotential cells within the basal layer of the epidermis or follicular structures. These cells 
are formed continuously during life and are capable of forming hair, sebaceous glands and apocrine 
glands. BCC typically occurs in areas of chronic sun exposure (UV radiation), which is thought to 
be the most important and common cause of BCC (Kricker et al, 1994). Also ionizing radiation, 
chemical carcinogens (eg. chronic exposure to arsenic), and possibly infection with human 
papillomaviruses, have been associated with BCC development. 
 
There are several clinical and histologic subtypes of BCC that may exhibit different patterns of 
behavior. Histologically, BCCs showing no differentiation are called solid BCC, with the subgroups 
of infiltrative and circumscribed. Those that differentiate toward hair structures are called keratotic, 
toward tubular glands, adenoid, and toward sebaceous glands, sebaceous BCCs. Clinically, five 
types occur: 1) Morpheaform (sclerosing, fibrosing) BCC arises as thin strands of tumor cells that 
are embedded in a dense fibrous stroma. The strands of infiltrating BCC tend to be somewhat 
thicker, and they have a spiky irregular appearance. 2) Nodular BCC is the most common variety of 
BCCs. Tumor cells of nodular BCC typically have large, hyperchromatic, oval nuclei and little 
cytoplasm. The cells appear rather uniform and tumor aggregates may be of varying sizes. Nodular 
BCCs usually have limited potential for growth, but they can occasionally be infiltrative and 
aggressive, and in the face, even destroy the eyes and nose. 3) Pigmented BCC differs from the 
previous subtype only by the brown pigmentation. 4) Superficial BCC presents as scaly patches or 
papules, which mainly occur on the trunk and has little tendency to become invasive. 5) 
Fibroepithelioma usually consists of only one raised, moderately firm nodule, mainly in the back. It 
is important to recognize the various types, since more aggressive therapy is often necessary for 
aggressive BCC variants, such as infiltrating and morpheaform BCCs (see Lever and Schaumburg-
Lever, 1990c; Ramsey 2001). 
 
MMP-1, unlike other collagenases (Varani et al, 2000), MMP-3 (Majmudar et al, 1994), MMP-11 
(Thewes et al, 1999), and both gelatinases, MMP-2 and MMP-9, (Pyke et al, 1992) are mainly 
expressed by stromal cells surrounding malignant epithelial cells in BCCs. In the more aggressive 
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morpheaform (infiltrative) BCCs and recurrent BCCs, MMP-7 localized at the tumor-stromal 
interface (Karelina et al, 1994), whereas it was not expressed in other BCC subtypes. MMP-13 
mRNA was seen in focal areas of keratinized cells and associated with terminal differentiation of 
epithelial cells as assessed with immunostaining for involucrin and apoptosis (Airola et al, 1997). 
Also TIMPs have been found in BCCs. According to Varani et al. (2000), MMP inhibitor activity 
mainly reflected the presence of TIMP-1. Significantly higher levels of TIMP-2 have been detected 
in BCC when compared to SCCs (Wagner et al, 1996). TIMP-3 was present in tumor cells at the 
tumor edge of infiltrative BCCs (Airola et al, 1998). 
 
Squamous cell carcinoma (SCC) can occur in many tissues and organs, including the skin, mouth, 
airways, esophagus, uterine cervix and vulva. Cutaneous squamous cell carcinoma (SCC) is the 
second most common form of skin cancer and frequently arises on the sun-exposed skin of the 
middle aged and elderly. Evidently, the primary cause of SCC is cumulative lifetime sun exposure 
(especially UVB). The mechanism of UV-induced photocarcinogenesis appears to involve the 
inactivation of the p53 tumor suppressor gene (Ziegler et al, 1994). Most SCCs arise from sun-
induced precancerous lesions known as actinic keratoses. On a continuum with actinic keratosis is 
SCC in situ, a subset of which is referred to as Bowen’s disease. Furthermore, ionizing radiation, 
immunosupressive agents, chronic inflammation, and human papillomavirus (HPV) infection may 
lead to the development of SCC. SCC is capable of local extension, regional lymph node and distant 
metastasis. Thus, high-risk SCC requires careful evaluation and treatment (Marks et al, 1988; 
Bernstein et al, 1996b; Goldman 2001). 
 
SCC is a malignant tumor of keratinocytes. SCC in situ is characterized by severe atypia of the basal 
layer, intraepidermal nests of atypical cells or full-thickness intraepidermal proliferation of atypical 
keratinocytes. The atypical keratinocytes often extend deep down hair follicles. With invasive SCC, 
malignant keratinocytes extend through the BM and into the dermis. The neoplastic cells 
demonstrate varying degrees of squamous differentiation and atypia. SCC cells are characterized by 
variations in the cell size and shape, hyperplasia and hyperchromasia of the nuclei, absence of 
intracellular bridges and keratinization on cells. Most dermatopathologists report SCCs as well, 
moderately or poorly differentiated, which behave more aggressively clinically. Increased depth of 
invasion of SCC is strongly associated with local recurrence, metastasis and death (see Johnson et 
al, 1992; Goldman 2001). 
 
Various SCCs express several MMP members (see Johansson and Kähäri, 2000). In cutaneous SCC, 
MMP-7 protein was expressed in tumor cells at the stromal interface surrounding tumor nests 
(Karelina et al, 1994). Together with MMP-9 (Karelina et al, 1993), they correlate with aggressive 
behavior of skin tumors. In SCCs of the skin and oral cavity, MMP-9 localizes to malignant 
keratinocytes at the tumor/stroma interface, which is due to interactions between tumor cells and 
adjacent fibroblasts (Lengyel et al, 1995; Borchers et al, 1997). Also the level of MMP-2 protein, 
together with MMP-9, is induced in SCCs of the skin when compared to BCCs (Dumas et al, 1999). 
Furthermore, MMP-13 mRNA expression was detected at the epithelial tumor front and less 
frequently in the surrounding stromal cells, while its potential activator, MMP-3, was expressed by 
stromal cells surrounding tumors (Airola et al, 1997). Also MMP-1 mRNA has been detected in 
tumor and/or stromal cells in SCC of the skin (Tsukifuji et al, 1999), while MMP-11 was expressed 
exclusively in stromal cells, as is typical of it (Asch et al, 1999). 
 
In SCCs of the head and neck (HNSCC), stromelysin (MMP-3, and -10) transcripts were localized 
in tumor and stromal cells along disrupted BM (Polette et al, 1991). MMP-3 immunoreactivity 
correlated with tumor size, tumor invasion, and the high incidence of lymph node metastasis in SCC 
of the oral cavity (Kusukawa et al, 1995). MMP-11 mRNA was detected in stromal cells next to 
invasive cancer cells of the HNSCC and the level of its expression correlated with increased local 
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invasiveness (Muller et al, 1993). MMP-13 mRNA was expressed by tumor cells at the invading 
front, but occasionally also by stromal fibroblasts. Its expression correlated with the invasion and 
metastasis capacity of the HNSCCs (Johansson et al, 1997c). MT1-MMP protein was shown to 
localize on the cell surface of tumor cells, especially at the invasive areas (Yoshizaki et al, 1997). Its 
mRNA has, however, been detected in stromal cells of the same cancer (Okada et al, 1995). 
Interestingly, a similar discrepancy has been reported for MMP-2 expression in HNSCC and in skin 
cancer (Pyke et al, 1992) in accordance with the role of MT1-MMP in the activation of MMP-2 
(Sato et al, 1994). Furthermore, the level of active MMP-2 may serve as a predictive marker of 
metastasis in oral SCCs (Kawamata et al, 1998). MMP-1 mRNA has been detected both in stromal 
fibroblasts surrounding invasive oral SCC, and in tumor cells (Polette et al, 1991; Gray et al, 1992; 
Sutinen et al, 1998). MMP-9 protein correlated with angiogenic markers and poor survival in 
HNSCC patients (Riedel et al, 2000). 
 
In esophageal SCCs, high levels of MMP-1, -2, and -3 expression have been shown (Shima et al, 
1992). MMP-1 is also associated with poor prognosis (Murray et al, 1998). MMP-13 protein was 
detected in tumor cells colocalizing with MT1-MMP, and their expression was related to cancer 
aggressiveness (Etoh et al, 2000). Furthermore, elevated protein expression of MMP-7, MMP-9 and 
MT1-MMP, as well as gelatinase activity, was detected in carcinoma cells correlating with the depth 
of tumor invasion (Ohashi et al, 2000). MMP-7 may also serve as a prognostic factor for patients 
with esophageal SCC (Yamashita et al, 2000). 
 
Cancer of the vulva may arise from the skin, subcutaneous tissues, glandular elements of the vulva, 
or the mucosa of the lower third of the vagina. Vulvar cancer is relatively rare, being responsible for 
approximately 5% of gynecologic cancers. Approximately 85–90% of these tumors are epidermoid 
cancers (SCC). It is primarily a disease of postmenopausal women. Intraepithelial cancer of the 
vulva in women in their 20s and 30s has increased remarkably in recent years coincidentally with an 
increase in the incidence of diagnosis of dysplasia and carcinoma in situ of the cervix. SCCs of the 
vulva usually show extensive local invasion to other pelvic organs and metastases in iliac lymph 
nodes. Epidermoid cancers may be graded histologically from I to III (Kurman et al, 1994). Grade I 
tumors are well differentiated, often forming keratin pearls; grade II tumors are moderately well 
differentiated; and grade III tumors are composed of poorly differentiated cells. The extent of 
underlying inflammatory cell infiltration into the stroma surrounding the invasive tumor is variable. 
Well-differentiated tumors usually have a good prognosis. However, the gross size of the tumor is 
the most significant factor in prognosis. The primary determinant of nodal metastases is tumor size. 
A variant of epidermoid cancer, verrucous carcinoma, is a locally invasive tumor that seldom 
metastasizes to regional lymph nodes (Smith et al, 1994). 
 
To date, there is only one report concerning MMPs in vulvar SCCs. MMP-13 was shown to be 
expressed especially in vulvar carcinomas showing metastasis to lymph nodes, and its expression 
was associated with the expression of MT1-MMP in tumor cells and MMP-2 in stromal cells. Also 
MMP-1 expression was detected in stromal as well as some tumor cells. In some samples, MMP-9 
protein colocalized with MMP-13 (Johansson et al, 1999). 
 
2.3.4.3. Therapeutic MMP inhibitors 
 
Currently, a number of clinical studies focus on testing MMP inhibitors as potential antineoplastic 
agents. The low basal expression of MMPs in normal adult tissues have made them a prominent 
therapeutic target in cancer and other diseases, as it has been assumed that their effects on normal 
cell functions would be minimal. Thus, the most efficient approach for cancer therapy would seem 
to be the inhibition of all MMP activity by either TIMPs or the administration of synthetic MMP 
inhibitors. Indeed, the first generation broad-spectrum MMP inhibitors did just that, but unspecific 
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action caused some side effects of arthralgia, probably due to their broad substrate specificity and 
because MMP activity is required for maintaining healthy joints in adult tissue. More recently, 
inhibitors that demonstrate some selectivity for specific MMP family members have been developed 
in an attempt to limit unpleasant side effects (see McCawley and Matrisian, 2000; Stetler-Stevenson 
and Yu, 2001). 
 
Theoretically, the ability of TIMPs to specifically inhibit the activity of several MMPs could result 
in a beneficial therapeutic effect. For instance, adenovirus-mediated delivery of TIMP-3 gene 
inhibits invasion and induces apoptosis in various normal and malignant cells (Bian et al, 1996; 
Ahonen et al, 1998; Baker et al, 1998). However, the lack of effective methods of systemic gene 
delivery has limited the clinical utility of this approach. Synthetic inhibitors designed to inhibit 
MMP activity work in a similar way to TIMPs by interfering with the catalytic machinery in the 
active site of the enzyme. The hydroxyamate inhibitor batimastat and its orally available analogue 
marimastat were the first inhibitors studied in detail. These compounds were designed to fit tightly 
within the active site of the MMP in a stereospecific manner (Brown et al, 1999; Hidalgo and 
Eckhardt 2001). The nonpeptidic MMP inhibitors, such as BAY 12-9566 and AG3340, were 
synthesized in an attempt to improve the oral bioavailability, pharmaceutical properties and 
specificity of the peptidic inhibitors. Specific peptide inhibitors may represent a useful alternative 
for selective targeting of therapeutic MMP inhibition in cancer. Gelatinase-specific inhibitors 
isolated from phage display peptide libraries suppressed migration of both tumor cells and 
endothelial cells in vitro, targeted to tumors and prevented tumor invasion and growth in animal 
models (Koivunen et al, 1999). 
 
Retinoids may be effective in cancer therapy by blocking MMP synthesis and decreasing tumor 
invasiveness (Schoenermark et al, 1999). Tetracycline derivates interfere with both the activity and 
the production of MMPs and inhibit tumor growth and metastases in preclinical models. Also 
bisphosphonates have been used to inhibit MMP activity (Hidalgo and Eckhardt, 2001). Besides 
strategies targeted to inhibit MMP activity, the degradation of MMP mRNA by antisense RNA or 
ribozyme techniques may also provide an efficient alternative to prevent tumor cell invasion 
(Hasegawa et al, 1998; Stetler-Stevenson and Yu, 2001). The advantage of antisense strategies is 
their selectivity for a specific MMP subtype, thereby potentially resulting in fewer toxic effects. The 
inhibition of MAP kinases involved in signal transduction can also inhibit MMPs and the invasive 
potential of cancer cells (see Hidalgo and Eckhardt, 2001). Similarly, MMP promoter activity can be 
inhibited, for instance, by preventing activation of AP-1 site by oligomers. 
 
Several synthetic inhibitors are in phase I/II/III trials for various forms of cancer. Phase III clinical 
trials using marimastat, batimastat and BAY 12-9566 alone or in combination with chemotherapy in 
patients with advanced lung, prostate, pancreas, brain, or gastrointestinal tract cancers showed no 
clinical efficacy. This may result from the fact that MMPs seem to be important already in the early 
stages of tumor progression, and inhibition may no longer be useful once metastases have been 
established. Thus, future trials should concentrate on patients with early stage cancers, and the 
measurements of MMPs levels from tissue or blood would help identifying patients more likely to 
respond to MMP therapy (Zucker et al, 2000). Although the development of specific MMP 
inhibitors may result in more effective compounds, the MMP system is, however, extremely 
complex, and it is not yet clear which subtypes should be targeted therapeutically to achieve 
antitumor effects (Stetler-Stevenson 1999). The dual role of MMPs in angiogenesis also emphasises 
the necessity to identify appropriate targets for MMP inhibition. 
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3. AIMS OF THE STUDY 
 
The principal aim of this study was to examine the role of MMPs- 12, -10 and -7 in epithelial 
cancers. It has been thought that the inhibition of MMPs collectively would be the most effective 
way to prevent cancer growth and metastasis. However, multiple roles for MMPs are becoming 
evident in cancer biology; for example MMP-7 and -12, may also inhibit cancer growth. Thus, 
further knowledge is needed on the actual role and contribution of individual MMPs to the multiple 
stages of tumorigenesis in different cancer types. The expression of certain MMPs might also be 
used as prognostic markers when planning the aggressiveness of tumor treatment. 
The specific aims of the study were as follows:  
1) To investigate the expression and role of metalloelastase (MMP-12), stromelysin-2 (MMP-10) 
and matrilysin (MMP-7) in UV-damaged and premalignant lesions of the skin, in basal cell 
carcinoma, and squamous cell carcinomas of the skin and vulva. 
2) To study the regulation of these MMPs in cultured epithelial cells, including primary 
keratinocytes, transformed HaCaT cells and various SCC cell lines. 
3) To study how angiostatin-generating MMPs (MMPs -7, -9 and -12) affect tumor progression. 
4) To evaluate whether there is correlation between the expression patterns of these MMPs and 
clinical behavior of tumors (e.g. aggressiveness, angiogenesis, metastasis and patient outcome). 
5) To investigate MMP-12 expression during development. 
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4. MATERIALS AND METHODS 
 
4.1. Tissue samples 
This study was approved by the Ethics Committee of the Department of Dermatology, University of 
Helsinki, University Central Hospital. 
 
Fetal tissues and bone samples (I): Formalin fixed, paraffin-embedded specimens were obtained 
from the Department of Pathology, Helsinki University Hospital (adult bone and bone lesions) and 
from Oulu University Hospital (fetal tissues). Fetal age was estimated by menstrual age and 
macroscopic and histological examination. All fetal material used for in situ hybridization originated 
from medical abortions at 7, 9, 10, 11, 12, 16, 17, 20, 21 and 23 weeks of gestation (n = 28). The 
following adult histological specimens were examined: normal bone and cartilage (n = 4), osteoid 
osteoma, chondroma, osteochondroma, osteoblastoma (n = 8), osteosarcoma (n = 4), and 
chondrosarcoma (n = 19). The diagnoses were confirmed by two experienced pathologists. 
 
Skin samples (II): Formalin fixed, paraffin-embedded archival specimens of solar elastosis (n = 18, 
mean age 74 y, head and arm), solar keratosis (n = 8, mean age 67 y, head and ankle), anetoderma (n 
= 4, mean age 33 y, back and thigh), and mid-dermal elastolysis (n = 3, mean age 31 y, abdomen, 
arm) were obtained from the Department of Dermatopathology, University of Helsinki. Samples of 
normal skin from two groups of adults (n = 7, mean age 23 y, back, buttock and neck; n = 7, mean 
age 72 y, abdomen, back and face) and children under 5 y of age (n = 3; neck, back and buttock) 
were also examined. 
Eight healthy individuals, aged 23-44, volunteered to photoprovocation and skin biopsies. The 
photoprovocation was done during winter as previously described (Hasan et al, 1997) with 
UVASUN (emission spectrum 340-400 nm) and with Philips (Eindhoven, The Netherlands) TL 
20W/12 (emission spectrum 280-370 nm) light sources. Briefly, a 5-8 cm area of intact skin was 
irradiated on three successive days with 100 J UVA or with a 1,5 minimal erythema dose of UVB. 
Skin biopsies were obtained from six volunteers 3-5 days after the last provocation, fixed in 
formalin and embedded in paraffin. Two subjects were biopsied 24 h after one single provocation 
and samples were snap-frozen immediately. The study was approved by The Ethical Committees of 
Oulu and Tampere University Hospitals. 
SKH-1 hairless mice were exposed to the sun spectrum of 90 % UVA and 10 % UVB radiation as 
previously described (Starcher et al, 1999). Briefly, groups of five mice were exposed for 30 s three 
times a week with the lamp (Dermalight 2001 mercury halide 400 w high pressure lamp with UVB 
filter) positioned 8 cm above the mice to provide 0,09 J/cm2 of total irradiation, which is equivalent 
to approximately 1 minimal erythema dose, for up to 25 weeks. Non-irradiated age-matched mice 
served as controls. 
 
Skin cancers (III, V): Formalin fixed, paraffin-embedded archival specimens of SCC and BCC 
were obtained from the Department of Dermatopathology, University of Helsinki. The diagnoses 
were confirmed by two experienced dermatopathologists. The following histologic specimens were 
examined: squamous cell carcinomas (SCC): grades I (n = 5/n = 9, respectively), II (n = 7/n = 9), III 
(n = 5), basal cell carcinomas (BCC) (n = 19) (histological subtypes: fibrosing (n = 11), keratotic (n 
= 3), adenoid (n = 5), actinic keratoses (n = 6, IV), melanomas (n = 12, II), and Bowen’s disease (n 
= 5). 
 
Vulvar SCCs (IV): The most representative samples from the formalin fixed, paraffin-embedded 
vulvar SCC specimens were selected from the files of the Department of Pathology, University of 
Turku, Finland. Samples were reclassified, sectioned, and processed for the study. The tumors were 
regraded (grade I, n = 11; grade II, n = 13; grade III, n = 9) according to Kurman et al (1994). 
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4.2. RNA probes 
The generation and specificity of MMP-3, MMP-7, MMP-10, MMP-13 and mouse metalloelastase 
probes have been described (McDonnell et al, 1991; Shapiro et al, 1992; Saarialho-Kere et al, 1994; 
Johansson et al, 1997a). A 650-bp fragment of MMP-12 cDNA (corresponding to nucleotides 600-
1250) was generated by PCR as previously described (Vaalamo et al, 1998), resulting in a product 
with SP6 (3´end) and T7 (5´end) RNA polymerase recognition elements. A 1240-bp fragment of 
MT1-MMP cDNA (Lohi et al, 1996) was subcloned to a pGEM vector containing an SP6 RNA 
polymerase recognition element. When linearized with BgI II, an antisense RNA probe could be 
transcribed in vitro containing 405 bp from 3´UTR of the MT1-MMP cDNA. The specificity of the 
probe was confirmed by sequencing. As a control for nonspecific hybridization, sections were 
hybridized with 35S-labeled sense RNA from bovine tropoelastin cDNA. The validity of this probe 
as a negative control has been confirmed by Northern (Prosser et al, 1989) and by in situ 
hybridization (Saarialho-Kere et al, 1992). In addition, negative control probes for MMP-3, MMP-
10, MMP-12, and MMP-14 transcribed in sense orientation were used. 
 
Table 2. Probes for in situ hybridization 
Probe (Study) Length bp/ 
Part of the seq. 
Genbank 
accession no. 
MMP-3 (V) 217 (1584-1801) XM_006271 
MMP-7 (II,IV) 800 (14-813) NM_002423 
MMP-10 (V) 175 (1568-1743) NM_002425 
MMP-12 (I-V) 651 (600-1250) NM_002426 
Mouse MMP-12 (II) 800 NM_008605 
MMP-13 (I, III) 511 (1532-2042) NM_002427 
MMP-14 (V) 405 (3´UTR) NM_004995 
 
4.3. In situ hybridization 
Hybridizations were performed on 5-µm sections as described in detail (Prosser et al, 1989). All 
sections were pre-treated with 1 µg/ml (bone samples: 2,5 µg/ml) of proteinase K and washed in 0,1 
M triethanolamine containing 0,25 % acetic acid. Sections were hybridized with 35S-labeled probes 
(4-5 x 104 cpm/µl of hybridization buffer) at 50-55°C for at least 18 hours in a humidified chamber. 
Slides were then washed under stringent conditions, including treatment with RNAse A to remove 
unhybridised probe. After 20-45 days of autoradiography, the photographic emulsion was 
developed, and the slides were stained with hematoxylin and eosin. Samples previously positive for 
MMP-3 (cutaneous wounds), MMP-7 (sweat gland tumors), MMP-10 (wounds), MMP-12 
(sarcoidosis), MMP-13 (skin cancer) and MMP-14 (breast cancer) were used as positive controls in 
each experiment. The slides were analyzed independently by two investigators. 
 
4.4. Immunohistochemistry 
Immunostaining was performed on sections parallel to those used for in situ hybridization by the 
avidin-biotin-peroxidase complex technique using Vectastain Elite ABC Kit (Vector Laboratories, 
Inc., Burlingame, CA) or Zymed Kit (Zymed Laboratories Inc., San Francisco, CA). Samples were 
deparaffinized, dehydrated and endogenous peroxidase was blocked with 0,3-0,6 % hydrogen 
peroxide. Treatment with normal serum was used to block non-specific staining. Primary antibodies 
(Table 3) were incubated for one hour at 37°C or overnight at 4°C in humidified atmosphere. 
Diaminobenzidine (DAB) or aminoethylcarbazole (AEC) were used as chromogenic substrates and 
Harris hematoxylin as counterstain, as described in detail (Saarialho-Kere et al, 1993). Sections 
were pretreated with trypsin (10 mg/ml), pepsin or microwaving, if necessary. Controls were 
performed with normal mouse or rabbit immunoglobulin or with pre-immune serum. Staining for 
revealing elastic fibers was performed with Weigert´s elastin stain (Weigert´s Resorcin-Fuchsin). 
Morphologic damage to collagen was assessed by van Gieson´s staining. 
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Table 3. List of antibodies used in immunohistochemistry 
Antibody (Study) Source Dilution/pre-
treatment 
MMP-12 (I) 4D2, R&D Systems, Minneapolis, USA 1:20 
MMP-12 (II, III) Belaaouaj et al, 1995 1:300/trypsin 
Cytokeratin (III-V) A0575; Dako A/S, Glostrup, Denmark 1:200/trypsin 
CD-68 (I, III-V) KP-1, M814, Dako, Carpinteria, CA 1:300/trypsin 
γ2-chain of laminin-5 (V) Dr. Karl Tryggvason, Karolinska Institutet, 
Sweden 
1:500/trypsin 
TGF-β1 (I, V) MAB1032, Chemicon International, Temecula, 
CA 
1:500 
MMP-2 (V) IM33L, Calbiohem, Cambridge, MA 1:200/trypsin 
Von Willebrandt factor/ 
Factor VIII-related antigen 
(IV) 
A0082, Dako, Carpinteria, CA 1:500/pepsin 
MMP-9 (IV) GE213, Diabor, Oulu, Finland 1:500/trypsin 
MMP-7 (II) Busiek et al, 1992; Saarialho-Kere et al, 1995 1:800 or 1:1000 
MMP-7 (II) IM40L, Calbiochem, Cambridge, MA 1:50 
tenascin (II) No. 1927, Chemicon, Temecula, CA 1:1000/trypsin 
versican (II) no. 270428, Seigaku, Tokyo, Japan 1:500 
Basic FGF (I) Oncogene, Calbiochem, Boston, MA 1:1000/microwave 
 
4.5. Quantitation of vessel density and macrophages 
Areas of highest vascularization, so called “hot spots“, were screened at a low magnification (x40-
x100). These areas typically occurred at tumor margins and, in some cases, inside the tumor but 
areas of tumor margins were focused on, if possible. Vascular density was defined as the mean 
vessel count of four areas considered to have the highest densities. Individual microvessel counts 
were made on a x160 field. Any clearly stained endothelial cell or cell cluster with or without lumen 
that was clearly separated from adjacent microvessels, other cells or connective tissue elements was 
counted as an individual vessel. The amount of CD68 staining was measured with image analysis 
software (Image-Pro Plus, version 4.0 for Windows, Media Cybernetics, L.P.). Four areas 
containing the highest amounts of CD-68-positive macrophages were screened as above and selected 
per section. Positive staining was calculated on x200 fields as %-area/whole area and mean values 
were recorded. Statistical analysis (Kruskall-Wallis test with Dunn's post test and Spearman´s 
correlation) was performed using GraphPad Prism version 3.00 for Windows (GraphPad Software, 
San Diego California USA, www.graphpad.com). 
 
4.6. Cell cultures 
Primary keratinocytes were established from adult abdominal or breast skin obtained at 
laparotomies or mammoplasties for non-malignant disease. Subcutaneous fat and deep dermis were 
removed, and the remaining tissue was incubated overnight at 0.25% trypsin in solution A (Gibco 
BRL, Life Technologies, Paisley, Scotland). After incubation, keratinocytes were scraped off from 
the epidermis and suspended in Keratinocyte Growth Medium (KGM, Gibco BRL, Life 
Technologies), containing 2% decalcified fetal calf serum (FCS) and supplemented with 5 ng/ml 
epidermal growth factor (EGF) and 50 µg/ml bovine pituitary extract (BPE). Keratinocytes were 
maintained in KGM supplemented with EGF and BPE. 
 
A431-cells (epidermoid carcinoma cell line, ATCC) and HaCaT cells (Boukamp et al, 1988), 
transformed human epidermal keratinocytes, were cultivated in Dulbecco´s modified Eagle´s 
medium (DMEM, Gibco BRL) containing 10% FCS, 1% penicillin-streptomycin and 1% sodium 
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puryvate. Immortalized human breast epithelial cells (MCF-10f, ATCC) were cultivated in a 
mixture of DMEM and Ham´s F12 medium (1:1) (Sigma-Aldrich, Saint Louis, MO), containing 1% 
penicillin-streptomycin and 1% sodium puryvate, as well as insulin (10 µg/ml, Gibco), 
hydrocortisone (0,5 µg/ml, Sigma), cholera toxin (100 ng/ml, Gibco), EGF (20 ng/ml, Sigma) and 
reduced Ca2+. Medium was supplemented with 5% horse serum, which had been treated with Chelex 
100 (BioRad Laboratories, Richmond, CA) to remove divalent cations. 
 
Forty-three SCC cell lines from primary and recurrent tumor and metastases of SCCs of the head 
and neck (skin, n = 7; larynx, n = 12; oral cavity, n = 22) were established at the time of operation in 
the Turku University Central Hospital (Johansson et al, 1997c). Human vulvar cell line UT-SCV-3 
was derived from primary grade II tumor (T2N2M0) (Johansson et al, 1999). Cells were cultivated 
in DMEM containing 10% FCS, 1% penicillin-streptomycin, 6 mmol/L glutamine and nonessential 
amino acids. 
 
The well-differentiated human chondrosarcoma cells HCS-2/8 (Takigawa et al, 1989) and more 
mesenchymal HTB-94 (SW1353, ATCC) chondrosarcoma cells were cultivated in DMEM 
containing 10% FCS, 1% penicillin-streptomycin and 1% sodiumbicarbonate. 
 
4.7. Cytokines, growth factors and matrices 
To study the regulation of MMP-12 expression, equal amounts of cells were plated on 24-well tissue 
culture plates. The following day, cells were repeatedly washed with PBS and incubated for 12-24 
hours in either serum-free medium without supplements or in medium containing 2 % serum. 
Analogously, all treatments were done either without serum (in 24 h and 48 h incubations) or with 2 
% serum in 48 h incubations. After this, the cells were treated with different cytokines and growth 
factors (Table 4). Cells without any treatment were used as a control. The cells were also cultivated 
on different matrices, including collagen I, collagen IV, laminin, fibronectin and Matrigel (Becton-
Dickinson, Bedford, MA). Matrigel was diluted 1:10 using serum-free medium according to the 
manufacturer’s instructions. After 24 or 48 hours total RNA was extracted from the cells. All 
treatments were done in triplicates and positive results were confirmed at least in three different 
experiments. 
 
Table 4. Cytokines and growth factors used in cell culture 
Cytokine/growth factor 
(Study) 
Concentration Source 
Basic FGF (I, IV) 10 ng/ml Oncogene, Calbiochem, Boston, MA/ 
PeproTech EC Ltd., Rocky Hill, NJ 
EGF (IV) 10-20 ng/ml Sigma, St. Louis, MO 
GM-CSF (IV) 10 ng/ml R&D systems, Minneapolis 
HGF (IV) 10-20 ng/ml Sigma 
IFN-γ (III-V) 20 ng/ml or 100 U/ml Sigma/Promega, Madison, WI 
IL-1β (IV) 10 ng/ml Roche Molecular Biochemicals, Mannheim, 
Germany 
KGF (IV, V) 10 ng/ml Sigma/PeproTech EC Ltd. 
PDGF (IV) 20 ng/ml Sigma 
TGF-α (V) 10 ng/ml PeproTech EC Ltd. 
TGF-β1 (I, III-V) 1-5 ng/ml Sigma 
TNF-α (I, III-V) 20 ng/ml Sigma 
 
4.8. Quantitative RT-PCR 
PCR primers (Sigma Genosys, Cambridge, UK) and probes (PE Biosystems, Warrington, UK) for 
MMP-12 and MMP-7 were designed using the computer program Primer Express 1.0. (PE 
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Biosystems) (Table 5). As controls, primers and probes for MMP-1 and MMP-10 were also 
designed. Fluorogenic probes contained a reporter dye (FAM) covalently attached at the 5' end and a 
quencher dye (TAMRA) covalently attached at the 3' end. To quantitate the starting material, 
endogenous controls were amplified in the PCR reactions. Controls included human GAPDH and 
ribosomal RNA control (18S rRNA) (Pre-developed TaqMan Control Reagents, PE Biosystems), 
both labeled with VIC reporter dye. 
 
Table 5. Primers and probes for Taqman quantitative RT-PCR 
MMP Forward primer (nts) Probe Reverse primer (nts) 
MMP-1 5´-CCACAACTGCCAAAT 
GGGCTTGA-3´(1032-1054) 
TCCCTTTGAAAAACCGGAC
TTCATCTCTGT (1107-1078) 
5´-GTCCTTGGGGTATCC 
GTGTAG- -3´ (1157-1137) 
MMP-7 5´-GCTGGACGGATGGTA 
GCA-3´ (630-647) 
TCTAGGGATTAACTTCCTGT
ATGCTGC (649-675) 
5´-AAGAATGGCCAAGTT 
CATGAG-3´ (698-677) 
MMP-10 5´-GACCTGGGCTTTATG 
GAGATATT-3´ (582-604) 
TCCTCGTTGCTGCTCATGAA
CTTGGC (668-693) 
5´-GCTTCAGTGTTGGCTG 
AGTGAA-3´ (720-699) 
MMP-12 5´-TGCTGATGACATACG 
TGGCA-3´ (765-784) 
CAGTCCCTGTATGGAGAC 
CCAAAAGAG (786-812) 
5´-AGGATTTGGCAAGCG 
TTGG-3´(834-816) 
 
Total cellular RNA from cells was extracted by using RNeasy miniprep-kit (Qiagen, Chatsworth, 
CA) according to the manufacturer´s instructions. RNA was then reverse transcribed to cDNA with 
TaqMan Multiscribe enzyme and random hexamers and used as a template in PCR reaction. Real-
time quantitative PCR reactions were performed with the ABI PRISM 7700 Sequence Detector 
System (PE Biosystems) as previously described (Rechardt et al, 2000). PCR amplifications were 
performed in a total volume of 20 µl, containing 5 µl cDNA sample, 1 µl human GAPDH 
endogenous control reagents, 100 nM of each primer and 100 nM of fluorogenic probe. The PCR 
was started with 2 min at 50°C and the initial 10 min denaturing temperature of 94°C, followed by a 
total of 40 cycles of 15 s of denaturing and 1 min of annealing and elongation at 60 °C. The same 
reactions were done by conventional PCR with the same primers but without fluorogenic probes. 
Finally, PCR products were analyzed in 3% low melting point agarose gel in the presence of 5 ng/ml 
ethidium bromide and visualized under UV light. 
 
4.9. Northern analysis 
Total cellular RNA was isolated using the single step method (Chomczynski and Sacchi, 1987). 
Aliquots of total RNA (10-20 µg) were fractionated on 0,8 % agarose gels containing 2,2 M 
formaldehyde, transferred to Zeta Probe filters (BioRad, Richmond, CA), and immobilized by 
heating at 80°C for 30 min. The filters were prehybridized for 2 h and hybridized for 20 h with 
cDNAs labeled with [α-32P]dCTP using random priming. The filters were then washed, finally with 
0,1 x SCC/0,1% SDS at 60°C and [32P]-cDNA/mRNA hybrids were visualized by autoradiography. 
The mRNA levels were quantitated by scanning densitometry of the autoradiographs using MCID 
software (Imaging Research Inc., St Catharines, Ontario, Canada) and corrected for the levels of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the same samples. The MMP-12 probe was 
the same as used for in situ hybridizations. In addition, human MMP-13 cDNA fragments covering 
the coding region and part of 3'-untranslated region, altogether 1931 bp (Johansson et al, 1997a), a 
2.0 kb human cDNA for human MMP-1 (Goldberg et al, 1986), and a 1.3 kb rat cDNA for GAPDH 
(Fort et al, 1985) were used for hybridizations. 
 
4.10. Western blot analysis 
To assay the production of MMP-12 protein, equal aliquots of the conditioned media of HaCaT cells 
were fractionated on 7.5% SDS-PAGE (III). Grade II chondrosarcoma (I) specimens were 
homogenized and suspended into lysisbuffer (Boehringer Mannheim). The amount of proteins was 
determined using Bradford’s test (BioRad Protein Assay) and 30-60 µg of protein was loaded in the 
gel. Proteins were separated on 8-10% SDS-PAGE and transferred to a Hybond ECL filter 
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(Amersham). After blocking in PBS containing 5 % milk and 0,1 % Tween-20, the membrane was 
incubated with monoclonal antibody against human MMP-12 catalytic domain (R&D Systems, 
Minneapolis) or with monoclonal antibody against human recombinant MMP-12 (R&D Systems, 
Minneapolis) in concentration 1-1,5 µg/ml, followed by the detection of specifically bound primary 
antibodies with peroxidase-conjugated secondary antibodies (1:10000) visualized by enhanced 
chemiluminescence (ECL) (Amersham). Antibody against 72-kDa gelatinase (MMP-2; 1 µg/ml, 
Oncogene, Calbiochem, Cambridge, MA) was used as a control. 
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5. RESULTS 
 
5.1. MMP-12 in fetal development and bone lesions (I) 
 
To study the production of MMP-12 during human fetal development, we examined its tissue 
distribution in the fetal tissue samples obtained at 6-12, 15-16 and 19-22 weeks of gestation, using 
in situ hybridization. No signal was detected in embryos of 6-7 weeks, but beginning at week 8, 
signal for MMP-12 mRNA was found in the hypertrophic chondrocytes of fetal cartilage (I, Fig. 1 
A,B). In addition, MMP-12 was expressed in the developing bone undergoing ossification, 
including extremities, ribs and limbs, while the remaining cartilaginous area with more primitive 
cells lacked signal for MMP-12 (I, Fig. 1 F,G). The signal was confined to chondrocytes in 
hypertrophic cartilage in most of the samples. In addition, in some samples MMP-12 was also 
expressed in the cells lining perichondrium next to developing bone (I, Fig. 1 C,D). At week 11, 
mRNA was also expressed in the mesenchymal tissue surrounding hypertrophic cartilage (I, Fig. 1 
H-J). Two samples of fetal calvarial bones from weeks 15 and 16 were negative. In the samples 
examined, MMP-12 mRNA expression could not be detected in any other tissues such as the skin, 
lungs, kidneys, intestine and neural tissue. Furthermore, no signal could be detected in samples 
hybridized with the sense MMP-12 probe (I, Fig. 1E). Since we and others have previously 
characterized the expression and regulation of MMP-13 in fetal bone development (Johansson et al, 
1997b; Ståhle-Bäckdahl et al, 1997), we were interested in comparing its expression with that of 
MMP-12. The expression pattern was very similar: MMP-12 and MMP-13 colocalized in 
hypertrophic chondrocytes in fetal cartilage and ossifying bones and also in the cells lining 
perichondrium (data not shown). 
 
MMP-12 expression in malignant and pre-malignant bone lesions (I). As we observed the 
restricted expression of MMP-12 in developing bone, we also examined its expression in adult 
human bone and bone lesions. Of the benign and malignant bone lesions, MMP-12 mRNA was 
detected only in chondrosarcomas. It was confined to CD-68-positive macrophages surrounding the 
tumor in 8/19 samples (I, Fig. 2 A,B). Furthermore, MMP-12 was expressed in chondrosarcoma 
cells inside the tumor in 8/19 samples, where no macrophages were detected (I, Fig. 2 E,F; 3 A,C,c). 
Samples examined represented chondrosarcomas of different grades (I-III) from primary and 
recurrent tumors. The samples were also immunostained with the monoclonal MMP-12 antibody to 
confirm the expression pattern obtained by in situ hybridization, and the results were alike. 
Immunosignal for MMP-12 was seen both in macrophages and cancer cells and, thus, MMP-12 
protein co-localized with the corresponding mRNA (I, Fig. 2 C-E). There was no correlation with 
MMP-12 mRNA expression or the aggressiveness of the tumor (I, Table I). However, MMP-12 
mRNA was seen in the same regions as MMP-13, the expression of which was more abundant than 
that of MMP-12 (I, Fig. 3 A,B,E,F). All other benign and malignant tumors examined, e.g. osteoid 
osteoma, chondroma, osteochondroma, osteoblastoma and osteosarcoma, were negative for MMP-
12, as were normal adult bone and cartilage.  
TGF-β1 and bFGF immunostainings were done on all chondrosarcoma samples, since TGF-β1 
upregulates MMP-13 in chondrocytes (Johansson et al, 1997b) and bFGF in chondrosarcoma (Uria 
et al, 1998). TGF-β1 was not, however, expressed in the same area as MMP-12. Basic FGF did co-
localize with MMP-12 and MMP-13 (data not shown). Based on our cell culture studies, it is likely 
that bFGF induces production of MMP-13 but not MMP-12. To confirm our findings in vivo, we 
assayed the production of MMP-12 protein from homogenized grade II chondrosarcoma specimens 
by Western blot analysis. Immunoreactive MMP-12 protein was detected in two different patient 
samples (I, Fig. 4C) and the estimated molecular weight corresponded to the proMMP-12 (55 kDa). 
As a control, same samples were analyzed with monoclonal antibody against MMP-2 which detected 
immunoreactive protein with an estimated molecular weight of 79 kDa. 
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Induction of MMP-12 mRNA by TNF-α in HTB-94 chondrosarcoma cells. To clarify the 
physiological role of MMP-12 in chondrosarcomas, we studied its regulation in HTB-94 
chondrosarcoma cell culture in the presence of bFGF, TGF-β1 and TNF-α. By conventional PCR, 
low levels of MMP-12 transcript were detected in both HTB-94 (I, Fig. 4A) and HCS-2/8 cells (data 
not shown). Total RNA from these cells was analyzed using quantitative real time-PCR method. 
Basal levels for MMP-12 mRNA expression were very low in control cells, but treatment w ith TNF-
α (20 ng/ml) resulted in a marked induction of MMP-12 mRNA production after 24 hours of 
treatment (I, Fig. 4 A,B). The induction was detected already after 12 hours (about 40-fold induction 
compared to control cells) and was even higher after 48 hours (data not shown). Basic FGF and 
TGF-β1 did not upregulate MMP-12 in these cells (I, Fig. 4A,B). 
 
5.2. MMP-12 and MMP-7 in actinic damage (II) 
 
Solar elastosis manifests sunlight-induced damage of the elastic fibers in the upper and mid-dermis. 
Immunosignal for MMP-12 was clearly seen in all 18 samples within the fragmented, distorted and 
thickened elastic fibers of the upper dermis stained with Weigert´s elastin stain (II, Fig. 1 A,D). 
MMP-7 protein was detected in thinner but also histologically abnormal elastic fibers, located 
deeper towards mid-dermis (II, Fig. 1 B,C,F). The morphology of collagen was better preserved in 
MMP-7 than MMP-12 -positive areas (data not shown). In 8/18 samples band-like staining under 
the BM for MMP-7 was also seen (II, Fig. 1E). Immunoreactivity for the MMP-7 substrate, 
versican, was detected in large areas of the upper and mid-dermis partly co-localizing with MMP-7 
(II, Fig. 1 F,G). Tenascin was only detected as a  linear band under BM, but not in any elastotic areas 
of the upper dermis (II, Fig. 1B). Elastotic areas did not show MMP-9 immunoreactivity (data not 
shown). 
 
Solar keratosis shows actinically damaged fibers in upper dermis, whereas keratinocytes manifest 
with variable degrees of atypia. Like in solar elastosis, immunostaining for MMP-12 was seen in 
damaged, amorphous elastic fibers in upper dermis (II, Fig. 2 A,G), whereas MMP-7 protein was in 
mid-dermis (II, Fig. 2 C,D). However, only 1/8 samples demonstrated staining for MMP-7 under 
BM (II, Fig. 2 C,E). In situ hybridization did not reveal any positivity for MMP-12 or MMP-7 in 
either elastosis or keratosis (II, Fig. 2I). MMP-7 was occasionally seen in sweat glands and hair 
follicles (II, Fig. 1E, 2E), as previously described (Saarialho-Kere et al, 1995; Karelina et al, 1994). 
Staining for versican partly co-localized both with MMP-7 and -12 (II, Fig. 2 A-C). As in solar 
elastosis, tenascin was detected as a continuous line under BM, but did not co-localize with MMP-7 
(II, Fig. 2 E,F). 
 
UVA/UVB exposed human skin showed histologically slightly dilated capillaries, increase in the 
number of lymphocytes and melanocytes and parakeratosis. Shrinkage of keratinocytes was seen 
especially in UVB-irradiated skin. In situ hybridization revealed no MMP-12 expression after acute 
UVA or UVB provocation (data not shown). Immunosignal was seen in a few stromal 
fibroblast/macrophage-like cells, but not in the epidermis (II, Fig. 3 A,B). Both MMP-7 mRNA and 
protein was seen in sweat gland epithelium, but no positive stromal cells were detected (II, Fig. 3 C-
E). The intensity of staining under BM after UVB provocation was clearly increased when 
compared to UVA irradiated samples (II, Fig. 3 C,D,G,K). This could be explained by the finding of 
MMP-7 immunopositive basal keratinocytes in 2 samples of frozen tissue obtained one day after 
UVB exposure (II, Fig. 3F). Versican was in the same area as MMP-7 under BM (II, Fig. 3 G,H,J). 
The amount of tenascin was increased after UVB compared to UVA provocation (II, Fig. 3 L,M). 
 
Normal skin samples from different parts of the body and from patients of different ages (n = 17) 
were examined. No MMP-12 mRNA or protein was seen in the samples. Instead, MMP-7 was seen 
in sweat coils and the luminal surface of sweat ducts in all samples. Fibril-like staining below basal 
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keratinocytes was seen particularly in the samples of young adults (buttock, back) (II, Fig. 4D) and it 
became fainter in the specimens of children (II, Fig. 4A) and controls over 70 years of age. In 
normal skin, staining for versican and elastin was detected in MMP-7 positive areas under BM (II, 
Fig. 4 B,E,F). Tenascin was seen as a partly interrupted line immediately below basal keratinocytes 
in the papillary dermis, not co-localizing with MMP-7 (II, Fig. 4 D,G). 
 
The hairless SKH-1 mouse has long been an experimental model to study the effects of chronic 
low-dose UVA and UVB irradiation on the histologic changes that occur during solar damage 
(Starcher et al, 1999). MME-positive stromal cells were infrequently detected in the stromal cells of 
the mid-dermis of age-matched non-UV-irradiated control mice (II, Fig. 5A). In samples taken 12 
days after starting repeated UV administration, signal for MME was more frequently seen in the 
stromal cells of the mid-dermis in the vicinity of dermal cysts, characteristic of hairless mice (II, Fig. 
5B). Abundant signal for MME was further observed in biopsies obtained 8 and 11 weeks after 
starting repeated UV irradiation. Signal was not detected in the epidermis or the epithelium of 
keratinizing cysts but in plump (II, Fig. 5A) macrophage-like or spindle fibroblast-like (II, Fig. 
5C,D) stromal cells. 
 
5.3. Expression of MMP-12 in epithelial cancers (III, IV) 
 
SCC, BCC, and other skin lesions (III). Expression of MMP-12 mRNA was detected in 16/17 
SCCs studied (III, Table I). The signal was found in epithelial cancer cells in 11/17 tumors (III, Fig. 
1 A,F). The cell specific localization was confirmed using cytokeratin and CD-68 
immunohistochemistry (III, Fig. 1 B,E). In 15/17 samples MMP-12 mRNA was also expressed by 
stromal macrophage-like cells (III, Fig. 1 A,F-H). Well-differentiated, non-invasive tumors (grade I 
SCCs) displayed considerably less positive cells than grade II and III tumors (III, Table I). In 
ulcerated SCCs, signal for MMP-12 mRNA was detected in macrophage-like cells just beneath the 
wound bed. MMP-12 protein expression was detected in all SCCs examined (n = 14) and it was 
found both in macrophages and cancer cells (III, Fig. 1 C,D,I) in the same region as mRNA -positive 
cells. Immunostaining for CD-68 was performed on serial sections in altogether 19 SCCs or BCCs 
to exclude the possibility that MMP-12 expressing cells in the middle of cancer nests would be 
macrophages. The staining demonstrated that part of the MMP-12-positive cells were macrophages, 
particularly those lying near the borders of tumor islands. However, MMP-12-positive cells were 
also detected inside cancer islands devoid of macrophages (III, Fig. 1 I,J). 
 
MMP-12 mRNA was expressed also in BCCs in 10/19 samples studied (III, Table I), but the 
expression was focal and not as abundant as that of MMP-12 in SCCs (III, Fig. 2A). MMP-12 was 
generally expressed by macrophage-like cells, but in 4/19 samples it was also detected in 
cytokeratin-positive cancer cells within the tumor islands (III, Fig. 2 C,D). MMP-12 protein was 
expressed in the same area as MMP-12 mRNA either in cancer cells (III, Fig. 2 B,G) or 
macrophages. Like in SCCs, MMP-12 was expressed in the wound bed of ulcerated BCCs by 
macrophages (III, Fig. 2 E,F), based on the microscopical appearance of MMP-12-positive cells, 
their presence in cytokeratin-negative areas, and the lack of data on MMP-12 production by 
fibroblasts or endothelial cells.  
 
Tumors representing Bowen’s disease were negative for MMP-12 except for one sample. No MMP-
12 expression was found in Clark grade II-IV melanomas (not shown). Normal skin has previously 
been shown to be negative for MMP-12 mRNA and protein (Vaalamo et al, 1999), and was also 
included as a negative control in the present in situ and immunostudies with similar results. No 
signal was detected using the sense MMP-12 cRNA probe. 
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SCC of the vulva (IV). To further elucidate the role of human metalloelastase in SCC progression 
and to investigate whether the pattern of its expression influences on tumor aggressiveness and 
patient outcome, we studied its expression in SCCs of the vulva. Expression of MMP-12 mRNA 
was observed in 31/33 SCC samples (IV; Table I). In 28 samples it was expressed in CD-68-positive 
macrophages (IV, Fig. 1 E,F), whereas in 10 samples in epithelial carcinoma cells (IV, Fig. 1 A-D). 
The epithelial origin of signal was assessed using CD-68 and cytokeratin stainings as well as 
histological examination. Generally, whenever MMP-12 mRNA was expressed in cancer cells, the 
samples were also histologically more aggressive and less differentiated (grade II/III tumors) than 
well-differentiated (grade I) tumors (P=0,0099) (IV, Table I). The presence of metastatic lymph 
nodes did not associate with MMP-12 expression in cancer cells, since in several such patients 
signal was only evident in macrophages. Macrophage-derived MMP-12 mRNA was more abundant 
in well-differentiated grade I tumors than in grade III tumors and, thus, correlated inversely to 
invasiveness (P=0,01). No MMP-12 expression was detected in intact vulvar epithelium or in the 
stroma under it (data not shown). The amount of signal for MMP-12, either in macrophages or 
cancer cells, did not correlate with lymph node metastasis or patient prognosis. Neither did the 
amount of macrophages differ between the grades. Furthermore, there was no correlation between 
macrophage-derived MMP-12 mRNA and a low amount of blood vessels. Overall microvessel 
density did not significantly vary between the grades, although microvessel density may serve as a 
prognostic factor in cancers (Weidner 1995). 
 
5.4. Expression and regulation of MMP-12 in cultured epithelial cells (III, IV) 
 
Expression of MMP-12 in HaCaTs and SCC cell lines by Northern analysis (III, IV). To 
confirm the ability of SCC cells to express MMP-12, we used Northern blot analysis to determine 
the expression of MMP-12 mRNA in four cell lines established from SCCs of the head and neck. 
Marked expression of MMP-12 mRNA was detected in UT-SCC-7 cells (III, Fig. 3A), established 
from metastasis of a cutaneous SCC and in UT-SCC-38 cells, established from primary SCC of 
glottic larynx. Both of these cell lines also expressed high basal levels of MMP-1 and MMP-13 
mRNA (III, Fig. 3A). In addition, MMP-12 mRNA was detected in cell line UT-SCC-17, 
established from metastasis of a SCC of supraglottic larynx (not shown). Instead, no expression of 
MMP-12 mRNA was detected in UT-SCC-15, a primary SCC tongue cell line, which also expressed 
very low basal levels of MMP-1 and MMP-13 mRNA (III, Fig. 3A). We also examined the 
expression of MMP-12 in vulvar SCC cells. In agreement with vulvar SCC samples in vivo, MMP-
12 was also expressed in SCC cells derived from grade II primary tumor (IV, Fig. 3 and Figure 7). 
In contrast to MMP-13, it was not induced by TNF-α in these cells, nor was it induced by TGF-β1 
or IFN-γ. 
 
We also assayed the amount of MMP-12 protein in the aliquots of conditioned media corresponding 
to an equal number of cells by Western blot analysis using a monoclonal anti-MMP-12 antibody. 
UT-SCC-7 cells from metastasis of cutaneous SCC produced immunoreactive proMMP-12 with an 
estimated molecular weight of 58 kDa, and its production was enhanced 2.6 and 7.5-fold by a 24-h 
treatment with TGF-β and TNF-α, respectively (III, Fig. 3B). 
 
Marked expression of MMP-12 mRNA was also detected in the transformed HaCaT keratinocytes 
using Northern blot hybridizations, and its expression was slightly (1.8-fold) enhanced by TGF-β, 
but not by TNF-α, both of which markedly enhanced the expression of MMP-13 mRNA in the same 
cells (III, Fig. 4B). In HaCaT cells the basal expression of MMP-12 mRNA was suppressed by 40% 
with IFN-γ (100 U/ml) (III, Fig. 4B). However, IFN-γ slightly augmented the expression of MMP-12 
mRNA in combination with TGF-β and TNF-α (III, Fig. 4B). In the same cells, IFN-γ potently 
inhibited the basal MMP-13 expression, as well as the up-regulation of MMP-13 mRNA levels by 
TGF-β and TNF-α (III, Fig. 4B). Interestingly, no expression of MMP-12 mRNA was detected in 
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normal epidermal keratinocytes treated with TNF-α, TGF-β, or IL-1 using Northern analysis (not 
shown). 
 
 
Figure 7. Expression of MMP-12 in vulvar carcinoma cell line UT-SCV-3. Cells were incubated for 24 h in serum-free 
DMEM alone (control) or in the presence of TNF-α (20 ng/ml), TGF-β1 (5 ng/ml), IFN-γ (100 U/ml), PD98059 (30 
µM), a specific inhibitor of ERK1,2 kinases or SB203580 (10 µM), a selective inhibitor of p38 MAPK, prior to total 
RNA isolation. Twenty µg aliquots were analyzed for the level of MMP-12, MMP-1, MMP-13 and GAPDH mRNA by 
Northern hybridization. 
 
 
Induction of MMP-12 mRNA in HaCaTs and epithelial MCF-10f cells by quantitative RT-
PCR (IV). Since no clear data on MMP-12 regulation in epithelial cells exist, we cultured 
keratinocytes, HaCaT, epithelial MCF-10f and A431 cells on different matrices in the presence of 
various cytokines and growth factors. Total RNA from these cells was analyzed using the 
quantitative real time-PCR method (Rechardt et al, 2000). Basal levels for MMP-12 mRNA were 
practically undetectable in keratinocytes (III, Fig. 4A), as already shown in vivo, and A431 cells. 
After 24/48 hours of treatment with various cytokines and growth factors, there was no significant 
upregulation of MMP-12 (EGF, GM-CSF, IFN-γ, IL-1β, KGF, PDGF, TGF-β1 and TNF-α) in 
these cells. 
In contrast, in MCF-10f cells, TGF-β1 (5 ng/ml) and TNF-α (20 ng/ml) induced the production of 
MMP-12 mRNA, but only after 48 hours of incubation. In MCF-10f cells basal levels of MMP-12 
mRNA were very low and the treatment with TGF-β1 resulted in marked induction, which was 
about 50-fold on both plastic and matrigel and about 20-fold on fibronectin (IV, Fig. 4A and data 
not shown). Also TNF-α induced MMP-12 mRNA on plastic (20-fold) and fibronectin (7-fold) (IV, 
Fig. 4A). Results were similar with (2 %) or without serum. In HaCaTs, basal levels of MMP-12 
mRNA were already high in agreement with our previous data, and treatment with TGF-β1 induced 
these levels about 6-fold on plastic (IV, Fig. 4A) and 2-fold on matrigel (data not shown). TNF-α 
did not seem to regulate MMP-12 in HaCaTs in accordance with the results from Northern analysis. 
As a control, regulation of MMP-1 was also studied. There was a strong upregulation of MMP-1 in 
HaCaT cells, when treated with EGF and cultured on collagen I (Pilcher et al, 1997) (data not 
shown). 
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5.5. Expression of MMP-7 and MMP-9 in SCC of the vulva (IV) 
 
We also studied the expression of MMP-7 and MMP-9, other angiostatin-generating MMPs. MMP-
7 mRNA was detected in 50% of the tumors. It was expressed by cancer cells in 14/33 specimens 
(IV, Fig 2 A-C) and in stromal cells surrounding cancer nests in 6/33 tumors (IV, Fig. 2 D-F) (Table 
I). Matrilysin expression tended to concentrate in grade II and III tumors. MMP-9 protein was 
usually detected in the stromal macrophages and neutrophils (IV, Fig. 1G). The amount of MMP-9 
producing stromal cells was lower in grade III than grade I-II cancers. In 13/33 samples, MMP-9 
was also detected in epithelial cancer cells at the invasive front (IV, Fig. 1G). Expression in the 
epithelium was more frequent in grade III than grade I tumors (IV, Table I). In most cases when 
tumor cells expressed MMP-12 they also expressed MMP-7 (6/9) or MMP-9 (5/9) or both (4/9). 
 
The regulation of MMP-7 in HaCaT cells was studied (unpublished data), as, although several 
reports on MMP-7 regulation in adenocarcinoma and other cells exist (see Wilson and Matrisian 
1998), little is known about its induction in transformed keratinocytes. After 24 and 48 hours of 
treatment with various cytokines and growth factors, TNF-α (20 ng/ml) clearly induced the 
production of MMP-7 mRNA in HaCaT cells (Figure 8). Instead, there was no significant 
upregulation of MMP-7 with other factors studied (bFGF, EGF, GM-CSF, IFN-γ, IL-1β, KGF, 
PDGF and TGF-β1) in these cells. Neither did direct contacts between cells and components of 
ECM induce the production of MMP-7, when cells were cultured on collagens I and IV, fibronectin, 
laminin-I or Matrigel. 
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Figure 8. TNF-α induces MMP-7 in HaCaTs. Cells were cultured in DMEM and stimulated for 48 hours with various 
cytokines and growth factors (5-20 ng/ml) as described in Materials and methods. Cells without treatment were used as 
controls. Total RNA was extracted, reverse transcribed and analyzed by real-time quantitative RT-PCR (Taqman, PE 
Biosystems) using GAPDH as an endogenous control. Results are shown relative to mRNA levels from control cells.  
 
 
5.6. Expression and regulation of MMP-10 in SCC cells (V) 
 
MMP-10 was expressed in 13/21 SCC samples by epithelial cancer cells (V, Fig. 1 A,B,b;2 A,E). It 
was generally more abundantly expressed in tumors with substantial inflammation, near CD-68 
positive inflammatory cells (V, Fig. 1 A,C). The tumors found negative were typically devoid of 
inflammation or necrosis (data not shown). There was no correlation between the number of cells 
expressing MMP-10 and the histological aggressiveness of the tumor (V, Table 1). However, highly 
differentiated tumors tended to be negative or showed only a weak signal for MMP-10 mRNA. 
Expression of MMP-3, a closely related enzyme to MMP-10, was also studied in a subset of SCC 
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samples (V, Table 1). Both stromal and tumor cells expressed MMP-3 mRNA (V, Fig. 2C), and 
only in 4/18 samples did it co-localize with MMP-10 (V, Fig. 2 A,C). 
 
MMP-10 mRNA was also expressed in BCCs in 11/19 samples studied (V, Table 1). Of the positive 
tumors, 8/11 represented the fibrosing subtype, and in six of them mRNA was detected in cancer 
cells, while in two others the expression was connected with ulceration (V, Fig. 3 A,B,G). In 
general, the expression was not as abundant as in SCCs and was located near necrotic areas at the 
tumor surface. MMP-3 expression was more abundant in most samples than that of MMP-10, and it 
was more often expressed by stromal cells surrounding tumor islands than by cancer cells (V, Fig. 3 
D,H,I,i; Table 1). Based on our cell culture studies, immunoanalysis for TGF-β1 was performed in 
cancers. Generally MMP-10 positive cells located in the vicinity of TGF-β1 positive areas (V, Fig. 3 
E,F). All specimens of Bowen’s disease and actinic keratosis were negative for MMP-10, the 
expression of which has not been found in normal intact skin (Saarialho-Kere et al, 1994). No 
specific signal was detected using the sense control probe (V, Fig. 1D). 
 
Since laminin-5 has been associated with the invasive capacity of several carcinomas (Pyke et al, 
1995), immunosignal for laminin-5 was examined in altogether 13 SCCs and 11 BCCs. MMP-10 
positive cells showed intracellular staining for laminin-5 both in the areas of ulceration and at the 
borders of invasive tumor islands (V, Fig. 2 A,B,E,F). However, laminin-5 was clearly more 
abundantly expressed so that the edges of many tumor islands deeper in the dermis were laminin-5 
but not MMP-10 positive. Gelatinase A, which is known to be able to degrade laminin-5 in 
epithelial cells (Giannelli et al, 1997), was not found in the same cells (n=14 SCCs, n=6 BCCs), but 
rather in fibroblasts surrounding cancer islands (data not shown). 
 
Forty-three cell lines established from primary and recurrent tumors and metastases of SCCs of the 
head and neck (Johansson et al, 1997c) were examined for the expression of MMP-10. No basal 
MMP-10 mRNA expression was detected in any of the cell lines derived from skin (n = 7), while 
two cell lines from the larynx (n = 12) and two from the oral cavity (n = 22) showed some basal 
expression (V, Fig. 5A and data not shown). To examine the regulation of MMP-10 mRNA by 
Northern blot analysis, we chose the UT-SCC-7 cell line, established from metastasis of a cutaneous 
SCC. Cells were treated with TGF-α, FGF-2, and KGF, all potent stimulators of keratinocyte 
proliferation. Marked MMP-10 mRNA abundance was detected in UT-SCC-7 cells treated with 
TGF-α (10 ng/ml) and KGF (10 ng/ml), whereas FGF-2 (10 ng/ml) had no marked effect (V, Fig. 
5A). The treatment of UT-SCC-7 cells with IFN-γ (100 U/ml) alone had no effect on MMP-10 
mRNA levels, whereas treatment with TGF-β1 (5 ng/ml) and TNF-α (20 ng/ml) slightly enhanced 
MMP-10 mRNA expression (V, Fig. 5B). Interestingly, exposure of UT-SCC-7 cells to IFN-γ in 
combination with TGF-β1 or TNF-α resulted in marked induction of MMP-10 expression (V, Fig. 
5B). Abundant expression of MMP-10 mRNA was also detected in HaCaT keratinocytes treated 
with TGF-β1, alone or in combination with IFN-γ (V, Fig. 5C). In contrast to UT-SCC-7 cells, TNF-
α alone or in combination with IFN-γ had no marked effect on MMP-10 expression. 
 
5.7. MT1-MMP expression in SCC and BCC (V) 
 
The production of MT1-MMP was examined, firstly, since its expression in BCCs was poorly 
characterized and, secondly, since the expression of MT1-MMP may correlate with the invasiveness 
of the tumor samples under investigation (Mori et al, 1997; Gilles et al, 1996). MT1-MMP mRNA 
was expressed in 19/21 SCCs studied and in 11 of them the signal was detected in cancer cells (V, 
Fig. 4 B,C,c). Otherwise MT1-MMP was abundantly expressed by stromal fibroblasts (V, Fig. 4 
D,E). With the exception of four samples (V, Fig. 4 A,B), MMP-10 and MT1-MMP had quite 
distinct expression patterns. In general, MT1-MMP was expressed deeper at invasive tumor islands 
(V, Fig. 3 A,C). In BCCs, MT1-MMP mRNA was detected more often than MMP-10 mRNA. It 
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was expressed in all fibrosing (11) and keratotic (3) BCC samples but not in adenoid BCCs. Unlike 
in SCCs, cells expressing MT1-MMP were not cancer cells, but stromal fibroblasts surrounding 
tumor islands (V, Fig. 3C; 4 F,G). Since MT1-MMP has been shown to degrade and co-localize 
with laminin-5 at least in colon and breast cancer (Koshikawa et al, 2000), we also compared its 
expression to laminin-5 immunopositivity. We found, altogether in 13 SCCs and 11 BCCs, that 
MT1-MMP mRNA was not expressed in the same cells as laminin-5 but rather in the stromal cells 
in the vicinity of laminin-5 positive cancer cells (V, Fig. 4 D,E). 
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6. DISCUSSION 
 
6.1. MMP-12 in development and chondrosarcomas 
 
Embryonic development requires coordinated programming of cellular processes such as cell 
migration, differentiation, apoptosis, angiogenesis, and ECM formation. MMPs and their inhibitors 
participate in the regulation of these fundamental processes as has been shown in many studies in 
vitro (see Vu and Werb, 2000). Expression of different human MMPs and TIMPs during fetal 
development has been shown in vivo in various tissues at specific time points (Karelina et al, 1994; 
McGowan et al, 1994; Terada et al, 1995; Airola et al, 1998; Robinson et al, 2001). We observed 
that MMP-12 is expressed during fetal development exclusively in the hypertrophic chondrocytes of 
the developing bone undergoing endochondral ossification, while the cartilaginous area with more 
primitive cells, and other tissues, lacked signal for MMP-12. In some samples MMP-12 was also 
expressed in the cells lining perichondrium next to developing bone. 
 
Endochondral ossification is a process where avascular cartilage is turned into highly vascularized 
bone tissue. Cartilage is usually highly resistant to vascularization, except during bone formation 
when hypertrophic cartilage becomes a target for capillary invasion and angiogenesis (Werb et al, 
1999). Mouse models implicate that several MMPs have an important role particularly in 
endochondral bone formation (see Werb and Chin, 1998). Both MMP-9 and MT1-MMP deficient 
mice have severe defects in endochondral ossification as well as in vascularization, although their 
defects are different (Vu et al, 1998; Holmbeck et al, 1999; Zhou et al, 2000). MMPs may play a 
role in generating biologically active fragments of ECM components, which could regulate early 
development. Resting hyaline cartilage has a lot of anti-angiogenic activities and it has been 
suggested that MMP-9 would regulate the release of an angiogenic factor from hypertrophic 
cartilage or inactivate an inhibitor (Werb et al, 1999). Thus, the lack of MMP-9 would lead to a 
decrease in vascular invasion. On the other hand, MMP-9, like MMP-12, has been suggested to be 
antiangiogenic, since it generates angiostatin from plasminogen (Dong et al, 1997; Patterson and 
Sang, 1997). Thus, MMP-12 might regulate angiogenesis during fetal bone formation as it does in 
wound healing (Madlener et al, 1998). Alternatively, MMP-12 may cleave matrix components of the 
bone anlage in order to initiate the formation of mature bone. MMP-12 can degrade heparan and 
chondroitin sulfate proteoglycans in vitro (Gronski et al, 1997), of which the latter, in particular, are 
present in cartilage. Furthermore, they are concentrated at sites where matrix calcifies during 
endochondral bone formation (see Poole et al, 1986). Interestingly, mouse cartilage proteoglycan 
degradation is mediated by macrophage metalloelastase (Janusz et al, 1999). 
 
Our findings, together with previous reports, suggest that MMPs could mediate the development of 
human bone from cartilage in a cascade-like manner and may well have several functions. For 
example, if MMP-12 can activate MMP-2, as shown in vitro (Matsumoto et al, 1997), it could in 
turn activate MMP-13, since the expression patterns of MMP-12 and MMP-13 were remarkably 
similar in developing bone (Johansson et al, 1997b). Also MMP-13 was strongly expressed in 
chondrocytes of hypertrophic cartilage and in cells lining periosteum (Ståhle-Bäckdahl et al, 1997; 
Johansson et al, 1997b). It has been shown in a model system that MMP-13 is activated by MMP-2 
during chondrocyte maturation and the combination of both proteinases is required to prepare 
cartilage matrix for subsequent calcification before endochondral ossification (D'Angelo et al, 
2000). A very similar pattern has been shown for MMP-10, as it was expressed in chondrocytes of 
the growth plate in the fetal rib, while MMP-3 was in osteocytes in surrounding fibrous tissue. 
Furthermore, both were also expressed by osteoblasts at sites of bone formation (Bord et al, 1998). 
Theoretically, they are both able to activate MMP-13 (see Nagase 1998). No skeletal abnormalities 
have been described in the MMP-12 knock-out mice (Hautamäki et al, 1997), suggesting that other 
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MMPs can compensate for its functions. Its actual biological role during ossification awaits further 
studies. 
 
Chondrosarcoma is the second most common malignant bone tumor, originating from cartilage cells. 
Primary chondrosarcoma arises de novo and has the ability to invade normal bone tissue. Patients 
often lack symptoms and tumors are large at the time of primary diagnosis. It is often difficult to 
predict the biological behavior of these tumors and thus, an objective prognostic marker would be 
extremely important (Unni 1996). Of all the bone lesions studied, MMP-12 was detected only in 
chondrosarcomas, both in malignant chondrosarcoma cells, and in macrophages, which is 
particularly interesting in the context of our findings in fetal cartilage. In agreement with our results, 
MMP-12 upregulation has been shown in chondrosarcoma using cDNA microarray technology 
(Hiller et al, 2000). Also MMP-1 and -9 proteins have been observed in the cells in the marginal 
areas of cartilaginous lobules (Kawashima et al, 1997), a pattern which is similar to that of MMP-12 
in our study. Furthermore, expressions of MT1-MMP, MMP-2 and TIMP-2 demonstrate correlation 
with the tumor grade (Sakamoto et al, 1999). Similarly, a recent work from Söderström et al. (2000) 
suggests prognostic value for the same MMPs when determining aggressiveness of 
chondrosarcomas. In addition, the ratio of MMP-1/TIMP-1 gene expression may serve as a 
prognostic indicator in patients with chondrosarcoma (Scully et al, 1999). In our study, the 
expression of MMP-12 either in macrophages or in cancer cells did not significantly correlate with 
the tumor grade, although aggressive grade III tumors tended to have a smaller number of MMP-12 
positive cells than better-differentiated tumors (V, Table I). The expression of MMP-12 may still be 
associated with malignant transformation of these tumors, since it is produced in chondrosarcomas 
by malignant cells, but not at all in benign bone lesions or normal bone or cartilage. Based on the in 
vitro substrate specificity of MMP-12 (Chandler et al, 1996; Gronski et al, 1997), it is possibly 
involved in the cleavage of aggrecan. This large proteoglycan is the major component of the ECM in 
the chondrosarcomas and MMPs are known to participate in its degradation in these tumors 
(Toriyama et al, 1998). 
 
Like during development, MMP-12 and MMP-13 mRNAs were expressed in the same or adjacent 
areas in chondrosarcoma. Basic FGF enhances the expression of MMP-13 in chondrosarcoma cells 
in vitro (Uria et al, 1998; Balbín et al, 1999), but it did not induce MMP-12 in chondrosarcoma-
derived HTB-94 cells in culture. Nor was MMP-12 upregulated by TGF-β1, which could still serve 
as the modulator of MMP-12 expression in chondrocytes during development, based on the similar 
expression patterns of MMP-12 and -13 in ossifying bone (Johansson et al, 1997b) and on the fact 
that it upregulates MMP-12 in other cells. In macrophages TGF-β1, however, inhibits cytokine-
mediated induction of MMP-12 (Feinberg et al, 2000). Instead of bFGF and TGF-β1, TNF-α, an 
anti-tumor agent and an inflammatory mediator predominantly released by activated macrophages 
(see Fiers 1991), strongly upregulated MMP-12 mRNA in chondrosarcoma cells in time-dependent 
manner. Interestingly, TNF-α also stimulates MMP-9 production in HCS-2/8 cells leading to ECM 
degradation (Hattori et al, 2001). Furthermore, TNF-α is involved in macrophage-associated 
angiogenesis (see Ono et al, 1999). Besides chondrosarcoma cells, TNF-α is known to induce 
MMP-12 expression in macrophages (Feinberg et al, 2000). Macrophages surrounding 
chondrosarcoma lobules may secrete TNF-α and induce MMP-12 production in cancer cells of these 
tumors. 
 
6.2. MMP-12 and MMP-7 in solar damage 
 
Excessive exposure to sunlight is a crucial predisposing factor for actinic damage and malignancies 
of the skin. Photoageing causes accumulation of elastolytic material, i.e. elastin and versican 
(Bernstein et al, 1995a; Bernstein et al, 1995b) in the upper and mid-dermis. This is accompanied by 
the degeneration of collagenous matrix. Both in solar elastosis and keratosis, we observed abundant 
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expression for MMP-12 protein in the areas of abnormal elastotic fibers in the upper dermal region 
where UV-induced damage is expected to be most prominent. Since MMP-12 is the most effective 
MMP against elastin, it probably takes part in a reparative remodeling process by trying to cleave 
this abnormal elastotic material or fibrillin (Ashworth et al, 1999). It has been previously shown, 
that UVA and UVB induce MMP expression in dermal fibroblasts or epidermal keratinocytes. 
Expression of MMP-1, -2, -3, and -9 could lead to degradation of collagens and also noncollagenous 
ECM components, including proteoglycans and BM proteins (see Kähäri and Saarialho-Kere, 1997; 
Fisher and Voorhees, 1998). In aortic aneurysms, MMP-12 also localizes to residual elastic fibers 
but not in intact elastin (Curci et al, 1999), which is in accordance with our negative results in 
normal skin, anetoderma and mid-dermal elastolysis. GM-CSF is induced at least in keratinocytes by 
UV-light (Schwarz et al, 1989) and can upregulate MMP-12 expression in macrophages (Kumar et 
al, 1996); thus, it could be a candidate for inducing MMP-12 in solar damage. UV-radiation could 
also lead to the recruitment of macrophages that are a natural source of elastases. In the light of our 
results with SCCs, it is interesting that the majority of SCCs in light-exposed areas may arise from 
pre-existing solar keratoses (Marks et al, 1988). 
 
MMP-7 protein was detected deeper in the dermis than MMP-12. The elastic bundles were less 
thickened and distorted and collagen better preserved in these areas. The epithelial nature of this 
enzyme suggests that dermal macrophages, rather than stromal fibroblasts, would be the source of it 
(Busiek et al, 1995; Halpert et al, 1996). MMP-7 can be induced by IL-1β and become activated by 
MMP-3, both of which are induced by UVB light. MMP-7 may enhance elastin degradation in 
photodamaged skin both as an elastase and as a leukocyte elastase inhibitor (Wilson and Matrisian 
1998). In vitro, MMP-7 can degrade decorin, a small proteoglycan binding to collagen (Bernstein et 
al, 1995a), and MMP-7 is able to release TGF-β from this complex (Imai et al, 1997), thereby 
contributing to its activation. The immunoreactivity was always more intense after acute exposure to 
UVB than UVA. No MMP-7 mRNA or protein was seen in keratinocytes in samples collected three 
days after UV exposure. However, in frozen tissue taken one day after irradiation, the basal 
keratinocytes were repeatedly MMP-7-positive. This discrepancy may reflect either different 
sensitivity of the antibodies when working on frozen tissue versus paraffin samples or true time-
dependent regulation. MMP-7 is able to cleave the β4-integrin present in hemidesmosomes (von 
Bredow et al, 1997) and thus, it could participate in the degradative changes occurring in the BM 
zone after UV exposure. The colocalization of versican and elastin has been shown (Zimmermann et 
al, 1994) as has the upregulation of versican in photoaged skin (Bernstein et al, 1995a). Versican 
and MMP-7 protein were expressed in the same areas of the middermis both in solar elastosis and 
keratosis and in the papillary layer of normal skin. Thus, it is possible that MMP-7 cleaves versican, 
as has earlier been shown in atherosclerotic lesions (Halpert et al, 1996). The expression of tenascin 
was also increased in solar elastosis and keratosis and in UVA/UVB irradiated skin in agreement 
with previous data (Tuominen et al, 1997; Filsell et al, 1999). Tenascin is an in vitro substrate of 
MMP-7, but due to their distinct expression patterns in our samples, they probably do not interact in 
solar damage. 
 
Metalloelastase mRNA was upregulated in macrophage-like cells in UV-irradiated hairless mice 
skin. Repeated treatment of the mouse strain with UVB results in clinical and histologic changes 
similar to those observed in photodamaged human skin, such as inflammatory infiltrate and elastotic 
changes in the dermis (Kligman et al, 1982; Schwartz 1988). However, there are differences 
between mice and human skin in the amount and distribution of elastin that should be noted when 
extrapolating results between species. Most of the signal for MME was detected in mid-dermis, 
where elevated collagen mRNA levels and inflammatory cells have been reported (Starcher et al, 
1999). No MMP-12 or MMP-7 mRNA was detected in human solar elastosis and keratosis 
specimens, suggesting that dermal macrophages secrete these enzymes over a long period of time 
and that the proteins accumulate after years of exposure to UV-light. MMPs are not usually 
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constitutively expressed, but upregulated in response to specific signals and, in general, secreted as 
soon as they are synthesized. No mRNA expression was detected in biopsies taken three days after 
acute UVA/UVB provocation. Based on the structure of MMP-12 and -7 promoter regions, UV-
activated AP-1 can stimulate the transcription of both. Maximal induction of AP-1 occurs after 1 
minimal erythema dose (Fisher et al, 1996), which is less than the dose given by us. A single UVB 
exposure can cause acute induction of MMP, which returns to basal levels after 48-72 hours. The 
induction of at least MMP-1, -2, and -9 is mediated by MAP-kinases, which are maximally activated 
within four hours after UV-irradiation, returning to baseline at 24 hours (Fisher and Voorhees, 
1998). It is possible that, had we obtained our samples earlier than three days after 
photoprovocation, we would have seen increased mRNA expression of MMP -12 or -7 in the dermis. 
However, our data suggests that long-term exposure of the skin to sunlight is needed to induce these 
MMPs in the dermis. 
 
6.3. Dual role of MMP-12 in epithelial cancers 
 
The expression of MMP-12 has been shown mainly in macrophages, having a role, e.g., in 
macrophage-related proteolysis of elastin in various pathological conditions. Our study was the first 
to demonstrate MMP-12 expression in squamous and basal cell skin cancers. Interestingly, MMP-12 
mRNA and protein were expressed both in vivo and in vitro not only by macrophages but also by 
transformed human keratinocytes (SCC cells and HaCaTs). Furthermore, the level of MMP-12 was 
higher in histologically more aggressive and poorly differentiated tumor types (grades II and III), 
suggesting a possible role in invasion process. Analogously, clinically more aggressive, fibrosing 
BCCs expressed MMP-12 more often than the keratotic or adenoid BCCs. Our findings were further 
substantiated by the fact that, in our previous studies on several benign skin disorders or wound 
healing, we had never detected MMP-12 mRNA in normal keratinocytes in vivo (Vaalamo et al, 
1999) or in culture, indicating that MMP-12 expression is specific to transformed epithelial cells. 
MMP-12 mRNA expression had previously been detected in breast cancer (Heppner et al, 1996) in 
macrophage-like cells and, recently, in tumor-infiltrating macrophages in Barrett’s esophageal 
adenocarcinoma (Salmela et al, 2001). Along with our findings in skin cancer, the only study 
demonstrating MMP-12 in cancer cells and not in macrophages in vivo was that of Gorrin-Rivas et 
al. (1998), in which MMP-12 was primarily expressed by epithelial hepatocellular carcinoma (HCC) 
cells. Later, MMP-12 has been described in colorectal carcinoma cells (Yang et al, 2001). Strong 
expression of MMP-12 has, furthermore, been described in immortalized mammary epithelial cell 
line (MCF-10f) by RT-PCR (Giambernardi et al, 1998). Expression of MMP-13, MMP-7 and MT1-
MMP have previously been detected in malignantly transformed keratinocytes in SCCs, but not in 
normal keratinocytes or in premalignant lesions of the skin (Karelina et al, 1994; Airola et al, 1997; 
Johansson et al, 1997c). Thus, their expression serves as a marker for the transformation and 
invasion capacity of SCC cells. In the same way, the amount of MMP-12-expressing malignant 
keratinocytes could correlate with the invasiveness of SCCs. 
 
Also in SCCs of the vulva, both macrophages and epithelial cancer cells expressed MMP-12 
mRNA. MMP-12-positive cancer cells were, however, only detected in grade II and III tumors, 
therefore correlating with histological aggressiveness and dedifferentiation of the tumors 
(P=0,0099). Interestingly, MMP-12 can degrade plasminogen into angiostatin, which can inhibit 
angiogenesis and thus probably slow down tumor growth (Dong et al, 1997; Cornelius et al, 1998; 
Dong et al, 1998). Therefore, in contrast to our results in two subtypes of SCCs, it could be 
hypothesized that more invasive tumors express less MMP-12. Indeed, the hepatocellular carcinoma 
and colon carcinoma patients whose tumors did not express MMP-12 mRNA produced less 
angiostatin and had less favorable prognoses than those whose tumors expressed high amounts of 
MMP-12 (Gorrin-Rivas et al, 1998; Yang et al, 2001). In fact, MMP-12 gene transfer has recently 
been implicated in gene therapy in animal models of melanoma and colon carcinoma (Gorrin-Rivas 
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et al, 2000b; Gorrin-Rivas et al, 2001). These discrepant results suggest that the role of MMP-12 in 
cancer progression is complex and may vary between tumor (or cell) types. This goes for other 
MMPs too. It is evident that the expression of certain MMPs is very different in the epithelial than 
in adenocarcinomas. Besides, Northern blot hybridization, without the examination of the cellular 
source of MMP-12 except in very few samples, was performed in the reports by Gorrin-Rivas et al. 
(1998) and Yang et al. (2001). Angiogenesis inhibiting effect of MMP-12 in cancer seems, 
however, convincing at least in mouse models. In agreement with the results of other groups, 
macrophage-derived MMP-12 mRNA expression was more abundant in grade I tumors than grade 
III tumors (P=0,01), implicating that the more MMP-12 positive macrophages there are, the less 
aggressive the behavior of the tumors is. However, the amount of signal for MMP-12, either in 
macrophages or cancer cells, did not significantly correlate with other clinicopathological 
characteristics, including lymph node metastasis or patient survival. Furthermore, macrophage-
derived MMP-12 mRNA did not correlate with low blood vessel density, as might be expected, if 
MMP-12 generates angiostatin in these tumors. It is entirely possible that other angiostatin 
producing MMPs, including MMP-3, -7, and -9, which are also expressed in SCCs (Karelina et al, 
1994; Airola et al, 1997), may contribute to this process. The sensivity of tumors to angiostatin in 
vivo may also differ. 
 
The expression of MMPs is regulated by cytokines and growth factors secreted by both tumor and 
stromal cells. The regulation of MMP-12 has been studied mainly in macrophages, in which IL-1β, 
M-CSF, PDGF-BB, TNF-α and VEGF upregulated MMP-12 mRNA (Feinberg et al, 2000), while 
TGF-β1 inhibited this induction. Our present data indicate that MMP-12 is strongly upregulated by 
TGF-β1 in transformed keratinocytes (HaCaTs) and epithelial cells (MCF-10f). TGF-β1 is a 
multifunctional peptide that elicits many cellular events essential for cancer progression, including 
the modulation of angiogenesis and regulation of MMPs and other proteases (see Wright et al, 
1993). Interestingly, it had biphasic action during skin carcinogenesis in mice, acting as a tumor 
suppressor at the early stages but later enhancing the malignant phenotype (Cui et al, 1996). TGF-β1 
generally downregulates MMPs but may have the opposite effect depending on the cell type and 
state of transformation (Massague 1990). Also TNF-α induced MMP-12 mRNA in MCF-10f cells. 
TNF-α is a pleiotrophic anti-tumor and proinflammatory cytokine predominantly produced by 
macrophages (Fiers 1991), but it is also involved in processes that contribute to tumor progression. 
MMP-12 has been shown to have a capacity to process the TNF-α precursor (Gearing et al, 1994). 
However, MMP-12 transcription was not induced by TNF-α or TGF-β1 in the vulvar SCC cell line 
used in our Northern analysis (III, Figure 3). Although TNF-α and TGF-β1 generally enhanced 
MMP-13 expression in vulvar cancer cell lines, there was some variability in response to these 
factors, indicating that cell lines are heterogeneous (Johansson et al, 1999). Thus, TNF-α and TGF-
β1 could still upregulate MMP-12 in SCCs in vivo, which is supported by the fact that both of them 
slightly enhanced the production of MMP-12 protein in cells from metastasis of cutaneous SCC as 
assessed by Western blot (II, Figure 3B). The induction of MMP-12 production with growth factors 
and cytokines happens through AP-1 site (Feinberg et al, 2000; Wu et al, 2000). Interestingly, ERK 
inhibitor PD90859 inhibited MMP-12 mRNA expression in vulvar SCC cells, while the inhibitor of 
p38 pathway, SB203580, had no effect (Figure 7, unpublished data). This implies that ERK1,2 
pathway is involved in the regulation of MMP-12 transcription. Expression of MMP-1 and MMP-13 
is dependent on p38 activity, in particular (Figure 7), which has also been shown in transformed 
keratinocytes (Johansson et al, 2000). Enhancement of MMP-9 expression was mediated by both 
p38 and ERK1,2 pathways (Johansson et al, 2000). 
 
This and other studies, have pointed out some major roles for MMP-12. As originally suggested, it 
is involved in pathological conditions that involve excessive degradation of elastin, such as 
atherosclerosis, emphysema or solar elastosis (Halpert et al, 1996; Hautamäki et al, 1997), where it 
is secreted by macrophages recruited to the tissue. It is also involved in the macrophage-mediated 
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invasion of BM and matrix; these processes are impaired in MMP-12 deficient mice (Shipley et al, 
1996b). In cancer, it may have a dual role. In cancer-associated macrophages it may function in host 
response and inhibit angiogenesis and tumor growth by generating angiostatin, most likely in the 
early phase of tumorigenesis. In cancer cells of SCC, it correlated with aggressiveness of the tumors 
and may actually promote ECM degradation and tumor growth in more invasive tumors, either 
directly or through MMP-activation cascades. Finally, it has a role during bone development, which 
may reflect its involvement in the regulation of capillary invasion and angiogenesis, degradation of 
matrix proteins to enable bone formation, or again, activation of other MMPs. 
 
6.4. MMP-7 and MMP-9 in SCC of the vulva  
 
Expression of MMP-7 mRNA in vulvar SCC cell lines has been previously shown, while its 
localization in these tumors hadn’t been systematically studied (Johansson et al, 1999). The 
expression of MMP-7 in our vulvar SCCs seemed to concentrate in grade II and III tumors. 
Although MMP-7 was predominantly detected in carcinoma cells, in some samples it was also 
expressed in stromal cells, which were most likely macrophages (Busiek et al, 1995). It has been 
shown that integrin α1 knock-out mice have decreased vascularization due to angiostatin generated 
by MMP-7 and -9 (Pozzi et al, 2000). Although capable of generating angiostatin, MMP-7 clearly 
promotes tumor progression. Overexpression of MMP-7 led to enhanced tumorigenesis in the mouse 
breast cancer model (Rudolph-Owen et al, 1998) and MMP-7 deficient mice developed fewer 
tumors in the colon cancer model (Wilson et al, 1997). Its histological expression has previously 
been shown to correlate with an aggressive phenotype in many cancers, and it is predominantly 
found in tumor epithelium, e.g. in gastric and colorectal cancers, SCC of the skin, prostate cancer 
and breast cancer (McDonnell et al, 1991; Karelina et al, 1994; Heppner et al, 1996; Nelson et al, 
2000). MMP-7 expression also correlates with poor prognosis in esophageal and colon carcinomas 
(Nelson et al, 2000; Salmela et al, 2001). It is overexpressed in colon adenocarcinomas, but also in 
benign polyps (Newell et al, 1994). Recently, MMP-7 was shown to induce angiogenesis in vivo in 
colon cancer model (Nishizuka et al, 2001). Thus, increased expression of MMPs may both confer 
invasiveness to the tumor cells and, paradoxically, lead to the production of molecules limiting their 
growth. 
 
The regulation of MMP-7 in transformed keratinocytes has not been explored in much detail. It has 
been shown that TNF-α upregulates the expression of MMP-7 mRNA in vulvar SCC cell lines 
(Johansson et al, 1999). Similarly, our results show that TNF-α effectively induced the production 
of MMP-7 mRNA in HaCaTs (Figure 8, unpublished data). This has also been shown in mesangial 
cells (Marti et al, 1992). MMP-7 is also induced in premalignant intestinal epithelial cells by TNF-α 
and by IL-1β (Lopez-Boado et al, 2000). Instead, TNF-α was unable to induce MMP-7 in 
macrophages or in primary keratinocytes (Busiek et al, 1995; Lopez-Boado et al, 2000). 
Furthermore, TGF-β1 or other factors did not upregulate MMP-7 in HaCaTs or in vulvar SCC cell 
lines (Johansson et al, 1999), although TGF-β1 has been reported to induce it in the squamous cell 
line, II-4 (Borchers et al, 1997). Thus, the effect of different factors on MMPs clearly depends on 
the cell type. 
 
Also MMP-9 expression has been described in SCC of the vulva (Johansson et al, 1999), where it 
co-localized with MMP-13 in some samples. Furthemore, MT1-MMP and MMP-2 colocalized with 
MMP-13 in these tumors, probably optimizing the conditions for cascade-like proteolysis, as they 
are known activators of proMMP-13, which in turn, can activate proMMP-9 (Knäuper et al, 1996c; 
Knäuper et al, 1997). In our studies of the MMP-9 expression pattern in a larger series of vulvar 
SCCs, it was mostly expressed in stromal neutrophils and macrophages. In histologically aggressive 
tumors it also appeared in epithelial cancer cells, resembling the pattern of MMP-12 to some extent. 
Stromal MMP-9 may perhaps have a role in host-defense, or angiostatin generation, although it has 
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been shown that MMP-9 supplied by reactive stromal cells also promoted skin carcinogenesis in a 
mouse model (Coussens et al, 2000). MMP-9 has been implicated in cancer invasion; it correlates 
with the malignant potential of many cancers and poor outcome of the patients (see Stetler-
Stevenson et al, 1996; Nelson et al, 2000). Furthermore, activation of MMP-9 coincides with the 
’angiogenic switch’ in premalignant lesions during squamous epithelial carcinogenesis (Coussens et 
al, 1999) and MMP-9 promotes tumor angiogenesis in other mouse tumor models as well (Yu and 
Stamenkovich, 1999; Bergers et al, 2000b), despite its ability to generate angiostatin. Thus, findings 
on both MMP-7 and MMP-9 indirectly support our hypothesis of MMP-12 having a dual role in 
cancer depending on, for example, tumor type or stage of tumorigenesis. 
 
6.5. MMP-10 and MMP-14 in skin cancer 
 
MMP-10 has been considered to contribute to the invasive behavior of tumor cells. Prior to our 
study, there was practically no data concerning MMP-10 expression in human cancers in vivo, 
however. By in situ hybridization, MMP-3 and MMP-10 expression had been shown in tumor cells 
along disrupted BMs and in stromal cells in close contact to cancer cells in head and neck carcinoma 
(Polette et al, 1991). However, their probe did not make a difference between MMP-3 and -10. 
Furthermore, by Northern analysis, abundant expression of both stromelysin mRNAs has been 
shown in human lung and head and neck tumors with a more probable local invasiveness (Muller et 
al, 1991). According to our results, despite marked similarities in substrate specificity and structure, 
MMP-3 and MMP-10 were expressed with very distinct patterns, indicating different regulation and 
role in cancer. Although most MMPs are seen in cancer stroma, MMP-10 was expressed only by 
cancer cells in SCCs, as well as in BCCs. The epithelial origin of MMP-10 is further substantiated 
by novel results on Barrett`s adenocarcinomas, in which MMP-10 is only occasionally expressed in 
epithelial cells in conjunction with ulceration (Salmela et al, 2001). Instead, MMP-3 was more often 
expressed by stromal cells both in SCCs and BCCs and was clearly more abundant than MMP-10 in 
BCC. No signal for MMP-10 was detected in Bowen’s disease or actinic keratoses, in agreement 
with data on MMP-3 (Tsukifuji et al, 1999). Differential expression patterns of MMP-3 and -10 
have also been demonstrated in developing human bone (Bord et al, 1998), during cutaneous wound 
repair (Saarialho-Kere et al, 1994), and in vitro; human keratinocytes express MMP-10, while 
fibroblasts express MMP-3 (Windsor et al, 1993). 
 
Previous studies have shown that the expression of MMP-10 is induced by phorbol ester, TGF-α 
and EGF in normal epidermal keratinocytes (Windsor et al, 1993) and by KGF, EGF, TNF-α and 
TGF-β1 in HaCaT keratinocytes (Madlener et al, 1996). Interestingly, most of the 43 SCC cell lines 
previously shown to be producing MMP-1 and -13 basally (Johansson et al, 1997c) were negative 
for MMP-10 mRNA. This suggests that malignant transformation per se is not enough to induce 
MMP-10, but rather inflammatory cytokines modify its expression. In our cell line from metastasis 
of cutaneous SCC (UT-SCC-7), TGF-α, KGF and TGF-β1 clearly upregulated MMP-10 
transcription. IFN-γ in combination with TGF-β1 and TNF-α resulted in marked induction of MMP-
10. Interestingly, the expression of two other MMPs relevant in cancer progression, MMP-1 and -13 
are also upregulated by the same cytokines (Johansson et al, 1997c) but inhibited by IFN-γ (Ala-aho 
et al, 2000). Tumor-infiltrating lymphocytes in SCCs express IFN-γ, which can inhibit the 
proliferation of SCC cells. Furthermore, high expression of IFN-γ in SCCs correlates with favorable 
prognosis (Kim et al, 1995; Arany et al, 1997). This observation, in the context of our finding that 
IFN-γ stimulates SCC cell MMP-10 expression, suggests that MMP-10 is not involved in the 
invasion of SCC cells, not at least directly, but may rather be induced by several cytokines and 
growth factors functioning in ulcerative phenomena and inflammatory matrix remodeling associated 
with skin tumors. 
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In inactive tissues, laminin-5 is predominantly a static adhesive substrate, while in a changing 
environment it has a major role in epithelial cell motility. It aids the migration and invasion of tumor 
cells by establishing focal adhesions to the matrix (Pyke et al, 1995; Tani et al, 1996). Several 
studies on a variety of cancers have reported increased expression of laminin-5. For instance, γ2 
chain of laminin-5 colocalizes with the invasive cells in cervical lesions and can serve as a marker 
for early invasion. It also correlates with poor prognosis in colon carcinoma and esophageal SCC 
(Skyldberg et al, 1999; Lenander et al, 2001; Yamamoto et al, 2001). However, the use of laminin-5 
expression as a marker for the prognosis in skin cancers is complicated, since, also during wound 
healing, migrating keratinocytes express laminin-5, and cutaneous SCCs are often ulcerated. MMP-2 
induces the migration of breast epithelial cells by cleaving and regulating the function of laminin-5 
(Giannelli et al, 1997). Recent results suggest that expression of MT1-MMP is the primary trigger 
for migration over laminin-5, whereas MMP-2, activated by MT1-MMP, may play an additional 
role, perhaps by enhancing the MT1-MMP effects (Koshikawa et al, 2000). In this study, MMP-10 
mRNA was expressed in SCCs by epithelial cells producing laminin-5, implicating a migratory 
status of these cells. However, laminin-5 was expressed more abundantly than MMP-10, particularly 
deeper in the invasive border of tumor islands. MT1-MMP and laminin-5 did not generally 
colocalize in the same cells, but MT1-MMP mRNA located in stromal cells next to laminin-5 
expressing cancer cells. Thus, it is possible that either MT1-MMP or MMP-10, or both, might 
cleave laminin-5 during keratinocyte motility in skin cancer. MMP-2 protein did not colocalize with 
laminin-5 and apparently does not cleave it during skin carcinogenesis. Interestingly, TGF-β1 is able 
to induce both MMP-10 (Madlener et al, 1996) and laminin-5 in keratinocytes (Kainulainen et al, 
1998). 
 
MT-MMPs have an essential role in the pericellular activation cascades of MMPs. The activation of 
stromal proMMP-2 by MT1-MMP at the tumor cell surface is considered to be a critical event in 
cancer cell invasion (Sato et al, 1994; Knäuper et al, 1998). MT1-MMP mRNA has been detected 
both in cancer and stromal cells in various cancers (Okada et al, 1995; Gilles et al, 1996; Heppner et 
al, 1996; Ohtani et al, 1996; Mori et al, 1997; Harada et al, 1998). Our results are similar, since we 
found MT1-MMP mRNA expression both in cancer cells and in stromal fibroblasts surrounding 
SCCs. MT1-MMP-positive cancer cells were detected especially at the invasive edge of tumor 
islands. Although high levels of MT1-MMP expression have been shown to correlate with 
invasiveness in many cancer types, we found no significant difference in the intensity of MT1-MMP 
expression between poorly or well-differentiated cutaneous tumors. A dual role has been suggested 
for MT1-MMP too: its expression in cancer cell surface might relate to invasive growth, while in 
fibroblasts it may participate in tissue remodeling processes caused by invasive cancer cells (Ohtani 
et al, 1996). MT1-MMP can activate latent MMP-13 (Knäuper et al, 1996c) and, based on previous 
data (Airola et al, 1997), may be serving this function at the epithelial front. In contrast to SCCs, 
MT1-MMP expression was found generally in stromal fibroblasts surrounding tumor islands in 
BCCs. This suggests that MT1-MMP produced by fibroblasts in BCC might have another task than 
that produced by cancer cells in invasive SCCs. The limited invasion potential of BCC supports this 
result. 
 
The expression of various MMPs and TIMPs in SCC and BCC of the skin in vivo is summarized in 
Table 6. Various MMPs might form a network, in which each MMP has a distinct role in the 
cleavage of particular matrix component or activation of other MMPs. Stromal cells are the major 
source of MMPs, but tumor cells, fibroblasts and inflammatory cells all express a distinct set of 
MMPs capable of complementing the proteolysis needed in tumor progression (see Kähäri and 
Saarialho-Kere, 1999; Curran and Murray, 2000). It seems that epithelial expression of MMPs is 
more common in SCCs than BCCs, which might be due to differences in the invasion capacity of 
these tumors. Low expression of TIMPs does not necessarily correlate with enhanced invasiveness, 
since malignant  and  metastatic tumors often express  TIMPs  in vivo. However,  MMPs are usually  
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Table 6. Expression of MMPs and TIMPs in cutaneous SCCs and BCCs 
 SCC BCC 
MMP Epithelium Stroma Epithelium Stroma 
MMP-1 + + - + 
MMP-2 + + - + 
MMP-3 + + - + 
MMP-7 + - + - 
MMP-9 + + - + 
MMP-10 + - + - 
MMP-11 - + - + 
MMP-12 + + (+) + 
MMP-13 + (+) + - 
MMP-14 + + - + 
TIMP-1 - - - + 
TIMP-2 - + - + 
TIMP-3 - + + + 
 
 
expressed more abundantly, since overexpression of TIMPs can block tumor growth (Imren et al, 
1996; Bian et al, 1996; Ahonen et al, 1998). Interestingly, MMP-12, MMP-9 and  MT1-MMP were 
all expressed both in tumor and stromal cells in SCCs so that epithelial expression was more 
frequent in invasive tumors when compared to less aggressive SCCs (or BCCs).This suggests that 
individual MMPs may have different roles depending on a cell type or state of transformation. If a 
particular MMP is expressed by a tumor cell, it may contribute to invasion, while, when expressed 
by a stromal or inflammatory cell, it may have another, such as regulatory or even protective role in 
host defence. The expanding knowledge on the role of MMPs in cancer suggests that their role is 
much more complex than initially thought. 
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7. SUMMARY AND CONCLUSIONS 
 
Coordinated breakdown, synthesis and remodeling of the ECM are crucial events in normal 
physiological situations, such as embryonic development. On the other hand, excessive matrix 
degradation occurs in pathological conditions including tumor invasion and metastasis. Numerous 
studies have provided evidence for the importance of matrix metalloproteinases (MMPs) during 
these processes. In this study, we examined the expression and regulation of metalloelastase (MMP-
12), stromelysin-2 (MMP-10), and matrilysin (MMP-7) in epithelial cancers. Furthermore, we 
studied the role of MMP-12 during human development, where a restricted expression of MMP-12 
was detected in hypertrophic chondrocytes in developing bone. Of the bone lesions, MMP-12 was 
detected only in chondrosarcomas both in macrophages and chondrosarcoma cells. Its expression in 
cultured chondrosarcoma cells was induced in response to TNF-α stimulation. 
 
MMP-12 expression was detected in BCCs and SCCs of the skin and vulva both in epithelial cancer 
cells and macrophages, as well as in SCC and transformed HaCaT cells in culture, whereas pre-
malignant tumors and primary keratinocytes were negative. However, MMP-7 and -12 proteins were 
also upregulated in macrophages in areas of elastolysis in solar damage and actinic keratosis, a 
condition that can develop into SCC. In vulvar SCCs, MMP-12 mRNA was expressed in cancer 
cells only in histologically more aggressive grade II/III samples, thereby correlating with 
aggressiveness and dedifferentiation of the tumors. In contrast, macrophage-derived MMP-12 
mRNA was most abundant in grade I tumors, thus predicting less aggressive behavior of the tumors. 
The amount of signal for MMP-12, regardless of its origin, did not significantly correlate with 
lymph node metastasis, amount of blood vessels or outcome of the patients. The production of 
MMP-12 was induced by TGF-β1 and TNF-α in cells from metastasis of cutaneous SCC as well as 
in epithelial MCF-10f cells, while only by TGF-β1 in HaCaTs. MMP-7 mRNA was mainly 
expressed by epithelial tumor cells and was strongly induced by TNF-α in HaCaT cells. MMP-10 
mRNA was expressed in SCCs and BCCs only in epithelial laminin-5 positive cancer cells with a 
pattern totally different from its close homologue MMP-3. MMP-10 was upregulated in cutaneous 
SCC cells by TGF-α and KGF, and by IFN-γ in combination with TGF-β1 and TNF-α both in SCC 
and HaCaT cells. 
 
In conclusion, this study shows for the first time that MMP-12 can be expressed in vivo and in vitro 
by transformed epithelial cells. The level of carcinoma derived MMP-12 correlates with histological 
aggressiveness, while that produced by macrophages predicts a less aggressive behavior of the 
tumors suggesting a dual role for MMP-12 in tumor progression. Our results suggest that MMP-12 
mRNA expression in macrophages might serve as a new prognostic marker in SCC patients. MMP-
10 expression does not seem to correlate with the invasive behavior of SCCs, but may be induced by 
the wound healing and inflammatory matrix remodeling events associated with skin tumors. 
Furthermore, MMP-12 plays an important role in ECM remodeling during fetal bone development 
and is induced when chondrocytes undergo malignant transformation. 
 
Interactions between tumor and its microenvironment result in the production of degrading enzymes 
crucial for each step of tumor progression, including invasion, angiogenesis and metastasis. MMPs 
not only degrade ECM components in cancer, but it is now becoming evident that they actually have 
multiple roles in carcinogenesis. Although the number of MMPs and their expression levels are 
generally increasing along with cancer progression, the correlation between the levels of various 
MMPs and malignant potential of cancers clearly varies between tumor types. Thus, the actual role 
and contribution of individual MMP members to the development of different cancers still need to 
be better understood in order to get information on which MMPs could be used as prognostic 
markers in directing cancer therapy and, especially, on which MMPs would be the best targets for 
inhibition with minimal side effects. 
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